   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 1 of 43 
  
COVER PAGE 
 
DCP Protocol #: WF-30917CD 
 
Local Protocol #: WF-30917CD 
 
A STEPPED-CARE TELEHEALTH APPR OACH TO TREAT DISTRESS IN 
CANCER SURVIVORS 
 
Consortium Name:   Wake Forest NCORP Research Base   
Name of Consortium Multi-  Glenn Lesser, MD 
Principal Investigator  Department of Internal Medicine 
  Section on  Hematology and Oncology 
  Wake Forest School of Medicine 
Medical Center Boulevard 
Winston-Salem, NC  27157 Telephone: (336) 716-0891 Fax: (336) 716-6275 E-mail address: glesser@wakehealth.edu   
 
Consortium Name:   Wake Forest NCORP Research Base Name of Consortium Multi-  Kathryn Weaver, PhD, MPH Principal Investigator   Associate Professor of Public Health S ciences 
     D e p a r t m e n t  o f  S o c i a l  S c i e n ces & Health Policy 
     M e d i c a l  C e n t e r  B o u l e v a r d  
     W i n s t o n - S a l e m ,  N C  27157 
     T e l e p h o n e :  ( 336)713-5062 
     F a x :  ( 3 3 6 )  7 1 6 - 7 5 5 4       E - m a i l  a d d ress: keweaver@wakehealth.edu 
 Organization Name:   Wake Forest School of Medicine   
Protocol Principal Investigator:  Suzanne C. Danhauer, PhD  
  Department of Social Sciences & Health Policy  
  Division of Public Health Sciences   Medical Center Boulevard   Winston-Salem, NC 27157 
                                                           Tele phone: (336) 716-7402  
  Fax: (336) 716-7554   E-mail address: danhauer@wakehealth.edu   
 
Organization Name:   Wake Forest School of Medicine   
Protocol Principal Investigator:  Gretchen A. Brenes, PhD 
 Department of Internal Medicine, Section on 
Gerontology and Geriatric Medicine 
  Medical Center Boulevard   Winston-Salem, NC 27157                                                            Tele phone: (336) 716-1103  
  Fax: (336) 716-6830 
  E-mail address: gbrenes@wakehealth.edu   
 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 2 of 43 
 Organization:     Wake Forest School of Medicine  
Investigator:   Kathryn Weaver, PhD  
  Department of Social Sciences & Health Policy  
  Division of Public Health Sciences    Medical Center Boulevard    Winston-Salem, NC 27157    Telephone: (336) 716-0891  
  Fax: (336) 713-6476  
  E-mail address: keweaver@wakehealth.edu   
 
Organization:      Wake Forest School of Medicine   
Investigator/Protocol Statistician:  Janet A. Tooze, PhD 
  Department of Biostatistical Sciences   Division of Public Health Sciences  
  Medical Center Boulevard    Winston-Salem, NC 27157    Telephone: (336) 713-3833   Fax: (336) 716-6427 
  E-mail address: jtooze@wakehealth.edu   
 
Organization:      Wake Forest School of Medicine   
Investigator:   Rakhee Vaidya, MD 
  Department of Hematology and Oncology 
  Division of Public Health Sciences  
  Medical Center Boulevard  
  Winston-Salem, NC 27157    Telephone (336) 713-3833   Fax: (336) 716-2774   E-mail address: ravaidya@wakehealth.edu   
 
Organization:  University of Alabama Investigator         Maria Pisu, PhD 
  Division of Preventative Medicine 
  Medical Towers 636 
  1717 11
th Avenue South 
  Birmingham, Alabama 35205    Telephone: (205) 975-7366   Fax: (205) 934-7959   E-mail address: mpisu@uab.edu   
 
Organization:   Wake Forest School of Medicine  
Wake Forest RB Statistician:   Emily V. Dressler, PhD 
  Division of Public Health Sciences 
  Department of Biostatistics and Data Science   Medical Center Boulevard 
 Winston-Salem, NC 27157 
 Telephone: (336) 716-0917  Fax: (336) 716-6427  E-mail address: edressle@wakehealth.edu  
    
 
 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 3 of 43 
 Grant #:  1 R21 CA198237-01A1 
   
Protocol Amendment #:  5  
Protocol Version Date:  12/09/2020 
 
Protocol History: 
Initial Version 12/21/2017 Not Activated 
Amendment 1 Version 03/16/2018 Activated 06/18/2018 
Amendment 2 Version 06/22/2018 Activated 08/10/2018 
Amendment 3 Version 09/19/2018 Activated 04/29/2019 
Amendment 4 Version 11/20/2019 Activated 04/27/2020 
 
 
 
   
 
Participating Organizations 
 
NCORP Limited Participation: Wa ke Forest NCORP Affiliates and S ub-affiliates 
 
 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 4 of 43 
  
CONTACT INFORMATION 
 
For regulatory requirements: For p atient enrollments: For data submission: 
Regulatory documentation must 
be submitted to the CTSU via the Regulatory Submission 
Portal. 
Regulatory Submission Portal: (Sign in at www.ctsu.org ,            
and select the Regulatory  
Regulatory Submission.)   
Institutions with patients 
waiting that are unable to use the Portal should alert the CTSU Regulatory Office immediately at 1-866-651-2878 
to receive further instruction 
and support.  Contact the CTSU Regulatory Help Desk at 1-866-651-2878 for regulatory assistance. Please refer to the patient 
enrollment section of the protocol for detailed instructions. 
 Data will be submitted to the WF 
NCORP Research Base.   
Address:  
WF NCORP Research Base  
Wake Forest Baptist Medical 
Center  
Building 525@Vine, 4th floor  
Medical Center Boulevard 
Winston-Salem, NC 27157  
 
Fax: (336) 713-6476  
Email: NCORP@wakehealth.edu 
 
Do not submit study data or forms 
to CTSU Data Operations. Do not 
copy the CTSU on data 
submissions.  
The most current version of the study protocol and all supporting documents  must be downloaded 
from the protocol-specific page  of the CTSU member’s website https://www.ctsu.org .  Access to the 
CTSU members’ website  is managed through the Cancer Therapy and  Evaluation Program - Identity and 
Access Management (CTEP-IAM) registration system and requires u ser log on with CTEP-IAM 
username and password. 
For clinical questions (i.e. p atient eligibility or treatment-r elated)  contact the Site Coordinator at 
Wake Forest NCORP Research Bas e at NCORP@wakehealth.edu.  
For non-clinical questions (i.e. unrelated to patient eligibili ty, treatment, or clinical data 
submission) contact the CTSU Help Desk by phone or e-mail:   
CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com .  All calls and 
correspondence will be triaged to the appropriate CTSU represen tative.  
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 5 of 43 
  
SCHEMA 
 
  
If PHQ-2 <2 and anxiety 
item <1,  
Not eligible for study  
If risk of harm to self and 
others refer for emergency 
room evaluation,           
Not eligible for study  
If No/Mild Symptoms for    
Depressive and Anxiety 
Symptoms,                
provide survivorship 
resources (Supportive Care 
& Prevention)              
Not eligible for study  
Brief initial screen with PHQ-2 and single 
anxiety item 
Determine Depressive 
Symptoms Score (PHQ-9)     
 
Mild: 1-7                   
Moderate: 8-14              
Severe: 15-27 
 
Determine Anxiety 
Symptoms Score (GAD-7)    
 
Mild: 0-9                   
Moderate: 10-14             
Severe: 15-21 
 
 
Screen with PHQ-9 and GAD-7
Stepped-Care   
Telehealth             
Low Intensity 
Self-guided CBT 
(cognitive behavioral therapy) workbook 
Bi-weekly check in 
calls with research 
staff  
Enhanced Usual Care        
 (EUC Control)                              
Survivorship resources 
Contact information for local mental health 
providers 
Stepped-Care 
Telehealth             
High Intensity 
Self-guided CBT 
(cognitive-behavioral therapy) 
workbook 
Weekly CBT by 
telephone with a 
trained therapis
t
 
Assign to group based on highest level of 
symptom from the PHQ-9 and/or GAD-7 (N=90) 
 
Severe Symptoms    
Randomize 
 
Moderate Symptoms    
Randomize 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 6 of 43 
  
 
 
STUDY SUMMARY 
 Endpoints: Feasibility (accrual, retention, adherence), anxiety , and depressive symptoms, cost.  
 Stratification Participants will be stratified by baseline scor e ≥15 on the GAD-7 and/or on the 
PHQ-9, indicating severe anxiety or depressive symptoms, and by  whether they qualified for the 
study by the GAD-7, PHQ-9, or both. 
 Study Sample: 90 participants  Study Duration: 13 - 15 weeks  
Brief Eligibility Criteria: 
 Age ≥18 years 
 Score ≥10 on the GAD-7 and/or a score ≥8 on the PHQ-9, indicati ng clinically significant 
anxiety or depressive symptoms, respectively. 
 Past history of treated Stage I, II, or III (newly diagnosed or  recurrent) of any of the 
following cancers: breast, colorectal, prostate, gynecologic (o nly uterine and cervical) and 
any stage lymphoma (Hodgkin’s or non-Hodgkin’s).   
 6-60 months post-treatment compl etion (surgery, chemotherapy, a nd/or radiation therapy) 
for cancer. Time frame applies to most recent completion of tre atment if participant had a 
cancer recurrence. It is accepta ble to be on hormonal therapies . 
 Participant resides in California, Georgia, Illinois, Kansas, M ichigan, Minnesota, 
Missouri, New Mexico, North Caro lina, North Dakota, South Carol ina, Virginia, 
Tennessee, or Wisconsin.  
 Study trained therapist in sta te where participant resides.  
 Must be able to speak and understand English. 
 Must have access to a telephone. 
 
  
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 7 of 43 
  
TABLE OF CONTENTS 
SCHEMA ........................................................ ............................................................... .................... 5  
STUDY SUMMARY ................................................. ............................................................... ......... 6 
1. OBJECTIVES .................................................... ............................................................... ....... 9 
1.1 Primary Objectives ............................................ ............................................................... .............. 9  
1.2 Secondary Obj ectives .......................................... ............................................................... ............ 9 
1.3 Exploratory Ob jectives ........................................ ............................................................... ............ 9 
2. BACKGROUND .................................................... ............................................................... ... 9 
2.1 Distress in Cancer Survivors .................................. ............................................................... .......... 9 
2.2 Rationale ..................................................... ............................................................... ................... 10  
3. SUMMARY OF STUDY PLAN ......................................... .................................................. 10  
4. PARTICIPANT SELECTION ......................................... ...................................................... 11  
4.1 Inclusion Criteria ............................................ ............................................................... ............... 11  
4.2 Exclusion Cr iteria ............................................ ............................................................... .............. 12  
4.3 Inclusion of Women  and Min orities ............................. ............................................................... . 12 
4.4 Recruitment and Re tention Plan ................................ ............................................................... .... 13 
5. INTERVENTION PARAMETERS (RETENTION, ADHERENCE, TREATMENT 
FIDELITY) ..................................................... ............................................................... ........ 14 
5.1 Study ret ention ............................................... ............................................................... ................ 14  
5.2 Adherence ..................................................... ............................................................... ................. 14  
5.3 Treatment F idelity ............................................ ............................................................... ............. 14  
5.4 Management of Study Risk ...................................... ............................................................... ...... 15 
5.5.  Crisis Protocol ............................................... ............................................................... ................ 15  
6.   REGISTRATION .................................................. ............................................................... .. 16 
6.1 Cancer Therapy Evaluation Program Investigator Registration Pro cedures ................................. 16  
7. CLINICAL EVALUATIONS AND PROCEDURES ........................... ................................ 19  
7.1 Intervention De scrip tion ...................................... ............................................................... .......... 19 
7.2.  Schedule of Events ............................................ ............................................................... ............ 20  
7.3 Baseline Testing/Pre- Study Eval uation ......................... ...............................................................  21 
7.4  Baseline Te sting............................................... ............................................................... .............. 24  
7.5 Participant Enrollment  and Randomization ...................... ............................................................ 25  
7.6 Evaluation During St udy Interv ention .......................... ............................................................... . 25 
7.7 Evaluation at Completion of Study Intervention – Week 13 (could  occur weeks 13 -15 only for 
High Intensity Participants): (vi sit must be completed between Week 12 and Week 15) ....................... 26  
7.8 End of Study .................................................. ............................................................... ................ 27  
7.9 Methods for Clini cal Proce dures ............................... ............................................................... .... 27 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION................ .................... 29  
8.1 Primary Endpoint .............................................. ............................................................... ............. 29  
8.2 Secondary Endpoints ........................................... ............................................................... .......... 29 
8.3 Off-Study Criteria ............................................ ............................................................... .............. 30  
8.4 Study Termination ............................................. ............................................................... ............ 30  
9. CORRELATIVE/SPECIAL STUDIES- N/A .............................. .......................................... 31  
10. SPECIMEN MANAGEMENT- N/A ...................................... ............................................... 31  
11. REPORTING ADVERSE AND SERIOUS ADVERSE EVENTS .................. ..................... 31  
11.1 Reportable Adverse Events ..................................... ............................................................... ....... 31 
11.2  Serious Adverse Events ........................................ ............................................................... ......... 31 
11.3 Selected Adverse Events ....................................... ............................................................... ......... 32 
12. STUDY MONITORING .............................................. .......................................................... 32  
12.1 Data Management ............................................... ............................................................... ........... 32 
12.2 Case Report Forms ............................................. ............................................................... ........... 32 
12.3 Source Documents .............................................. ............................................................... ........... 32 
12.4 Data and Safety M onitoring Plan ............................... ............................................................... .... 33 
12.5 Sponsor or FDA Monito ring ..................................... ............................................................... ..... 33 
12.6 Record Ret ention .............................................. ............................................................... ............. 33  
13. STATISTICAL CONSIDERATIONS .................................... ............................................... 34  
13.1 Study Design/Description ...................................... ............................................................... ........ 34 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 8 of 43 
 13.2 Randomization/St ratifica tion .................................. ............................................................... ....... 34 
13.3 Sample Size ................................................... ............................................................... ................ 35  
13.4 Primary Objective, Endpo int(s), Analysis Plan ................. ........................................................... 35  
13.5 Secondary Objectives, Endpoi nts, Analysis Plans ............... ......................................................... 35  
13.6 Exploratory Objectives, E ndpoints, Analysis Plans ............. ......................................................... 36  
13.7 Reporting and Exclusions ...................................... ............................................................... ........ 36 
13.8 Evaluation of Response ........................................ ............................................................... ......... 37 
REFERENCES .................................................... ............................................................... ............. 38  
 
Appendices: 
 
A01 Addenda 
A02 Pre-Visit Form 
A03 Pre-Screening Form A04 Screening Form A05a BL_Self Report Measures Letter A05b BL_Self-Report Measures 
A06 Baseline Interviewer-Administered Measures and Chart Review  
A07 Enrollment Form 
A08 Randomization Form A09 CBT Workbook A10a ERS Ltr Template_High and Low Intensity A10b Expectancy Rating Scale 
A11 Week 7 Mid-Assessment Interviewer-Administered Measures 
A12a Wk13_Self-Report Measures Ltr A12b Wk13_Self-Report Measures A13 Week 13 Interviewer-Administe red Measures and Chart Review 
A14 Telephone Script/Manual for Low-Intensity Group 
A15 Psychotherapy Manual fo r High-Intensity Group 
A16 Stepped-Care Telehealth ( High Intensity) Progress Note 
A17 Working Alliance Inventory: Therapist A18 Telehealth Therapist Adherence & Competency Ratings-CBT 
A19 Low Intensity Check-In C alls Adherence Rating Form 
A20 EUC Survivor Resources 
A21 Crisis Protocol and Crisis Protocol Event Form 
A22 Safety: Adverse Event Form A23 Participant Status Change Form A24 Tracking Log (Implementation Costs) A25 List of Psychotropic Medication 
A26 Measures and Documents 
    
 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 9 of 43 
  
1. OBJECTIVES 
 
1.1 Primary Objectives   
 
1.1.1.  To determine feasibility (recruitment, accrual, retention, adhe rence) of a RCT of a stepped-care 
telehealth mental health intervention (tailored to symptom leve l) versus enhanced usual care in 90 
post-treatment cancer survivors with moderate or severe levels of emotional distress (anxiety 
and/or depressive symptoms). 
 
1.2 Secondary Objectives   
 
1.2.1.  To obtain preliminary data on the efficacy and variability of a  stepped-care telehealth mental 
health intervention (tailored to  symptom level) versus enhanced  usual care for reducing emotional 
distress (anxiety and/or depressive symptoms) in 90 post-treatm ent cancer survivors. 
 1.2.2.  To obtain preliminary data on the efficacy and variability of a  stepped-care telehealth mental 
health intervention (tailored to  symptom level) versus enhanced  usual care for secondary 
outcomes (sleep disturbance, fa tigue, fear of recurrence, cance r-related distress, and QOL) in 90 
post-treatment cancer survivors. 
 1.2.3.  To determine costs associated w ith both stepped-care telehealth  and enhanced usual care 
interventions from the perspec tive of a healthcare provider. We  will determine costs of 
intervention implementation and health care utilization in all arms over the course of the 
interventions. 
 
1.3 Exploratory Objectives
  
 
1.3.1.  To examine potential differential effects of the intervention on anxiety, depression, sleep 
disturbance, fatigue, fear of recurrence, and QOL, by gender, a ge, race/ethnicity, rural v. urban 
status, stratification arm (mode rate, severe), and psychotropic  medication use at baseline.  
 1.3.2  To examine mediating effects of  expectancy ratings of the inte rvention on anxiety and 
depression. 
 
2. BACKGROUND 
 
2.1 Distress in Cancer Survivors  
 
Psychological concerns are among the most commonly reported unm et needs among post-treatment 
cancer survivors.
1 Psychosocial distress, including anxiety and depressive sympto ms, is also common.2–14 
Up to 54% of post-treatment cancer survivors report clinically significant distress,4,15 which is associated 
with multiple adverse outcomes , including decreased quality of life (QOL),10,16,17 functional 
limitations,18,19 poor sleep,20,21 increased pain,14 and – particularly for those with elevated depressive 
symptoms – increased mortality.22,23 The Institute of Medicine has  emphasized post-treatment 
survivorship as a “distinct ph ase of cancer care,” with a need for ensuring delivery of appropriate care for 
cancer survivors.24 The need for interventions to reduce psychosocial morbidity in  post-treatment cancer 
survivors is critical.6,25 Psychosocial interventions for  post-treatment cancer survivors  may improve 
mental and physical health, pot entially offsetting increased he alth care costs among distressed cancer 
survivors.26  
 Mental health issues are more prevalent among the 2.8 million U S cancer survivors living in rural 
(versusnon-rural) areas,
27 further illustrating how the “burden of cancer is magnified am ong the US rural 
population.”28 Rural cancer survivors report more mental health concerns than non-rural cancer 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 10 of 43 
 survivors,29 yet psychosocial care for can cer survivors is scarce in many r ural areas.15,24,28,30 Almost 21% 
of U.S. cancer survivors reside in rural areas,25,27 and over half of rural coun ties have no mental health 
professionals.31 Recent studies found poorer accessi bility to mental health pro fessionals29 and higher 
levels of unmet needs3  in rural cancer survivors. Interventions that are accessible t o post-treatment cancer 
survivors experiencing significan t distress may reduce this can cer heath disparity. 
 
2.2 Rationale 
 
Noting the need for evidence-based cancer survivorship care, th e American Society of Clinical Oncology 
(ASCO) published guidelines for screening, assessment, and care  of psychosocial distress (anxiety, 
depression) in adults with cancer.6 These guidelines recommend screening all adults with cancer fo r 
distress and treating those with moderate or severe symptoms us ing a stepped-care approach tailored to 
distress severity. While these guidelines apply to survivors wi th all cancer types across the cancer 
treatment and survivorship continuum, we have chosen to focus o n survivors with non-metastatic breast, 
colorectal, prostate, uterine ,  and cervical cancers , as well as those with any stage lymphoma (Hodgkin’s 
or non-Hodgkin’s).  Further, we ha ve focused on the post-treatm ent survivorship period 6 months-5 years 
post-treatment because distress may be more likely to be assess ed and addressed after treatment 
completion. A significant minority of post-treatment survivors is at risk for anxiety and depression 
symptoms during the five years following the end of treatment a nd accessible interventions are needed to 
treat them.  The purpose of this study is to test a method of implementing t his stepped-care approach in community 
oncology practices caring for cancer survivors, using self-dire cted and stepped-care telehealth approaches 
based on cognitive-behavioral the ory. Our approach is based on a previous trial of telephone-based 
cognitive behavioral therapy for rural older adults with Genera lized Anxiety Disorder (NIMH 
1R01MH083664: The Tranquil Moments Study; PI: Brenes), which ha s demonstrated high acceptability 
and efficacy for reducing anxiet y, worry, and depressive sympto ms in a rural geriatric population.
32 This 
protocol adapts the methods of the previous trial to bring psyc hosocial care to underserved cancer 
survivors, many of whom have minimal or no access to mental hea lth providers. Cancer survivors will be 
recruited through multiple NCI Community Oncology Research Prog ram (NCORP) sites through the 
NCI-funded Wake Forest NCORP Rese arch Base (WF NCORP RB). 
 We will obtain data on feasibilit y, outcome variability, and ef ficacy for designing a subsequent fully 
powered randomized controlled trial (RCT) assessing the effects  of the intervention on distress in cancer 
survivors. In the planned larger study, we anticipate that this  intervention will: (a) reduce treatment 
barriers for post-treatment cancer survivors; (b) enhance avail ability of psychosocial treatment (through 
use of telephone sessions and a workbook); and (c) result in re ductions in anxiety and depressive 
symptoms in cancer survivors.  3. SUMMARY OF STUDY PLAN 
 
This study compares a stepped-care telehealth intervention (tai lored to level of symptomatology and 
designed to reduce anxiety and depressive symptoms) with enhanc ed usual care (EUC). Participants with 
no/mild symptoms will be provide d survivorship resources and wi ll not be included in the trial. 
 
A total of 90 particip ants will be randomized.  Study screening will be completed by a Research Nurse or 
an appropriate designated research staff member at each NCORP c omponent. Assuming an accrual rate of 
approximately 8-9 randomized participants per month, we expect study recruitment to be complete within 
11 months.  
Referred participants will waive documentation of informed cons ent to complete the PHQ-2 and single 
anxiety question. If a participant scores ≥ 2 on the PHQ-2 or ≥  1 on the anxiety question, he/she will be 
invited to complete the full screening assessment to determine study eligibility. The participant will 
complete the Abbreviated Verbal Consent at this point. We are a sking to waive the following elements of 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 11 of 43 
 consent for this second step of screening: disclosure of approp riate alternatives, statements regarding who 
may access the participant’s medical record for verification, a nd compensation for injury. If they meet all 
eligibility criteria and want to participate in the randomized trial, they will provide full informed consent 
for study participation. Train ed research staff members at each  NCORP component will obtain full 
informed consent from all inter ested and eligible potential par ticipants. 
 In accordance with ASCO guidelin es, participants with no/mild s ymptoms will be provided with written 
survivorship resources (a letter that contains a link to the Na tional Cancer Institute booklet “Facing 
Forward: Life after Cancer Tr eatment”) and will not be randomiz ed (Appendix 20). Participants with 
either moderate or severe distress (anxiety or depressive sympt oms) will be randomized into stepped-care 
telehealth (tailored to level of  symptoms) or EUC. For particip ants with moderate symptoms (PHQ-9: 8-
14; GAD-7: 10-14), low-intensity  stepped-care telehealth will c onsist of a self-guided cognitive 
behavioral therapy (CBT) workbook to reduce anxiety and depress ive symptoms and biweekly (every two 
weeks) check-in calls from research staff at NCORP components. On the biweekly check-in calls, 
research staff from NCORP components will provide minimal suppo rt and will administer the scripted 
“Telephone Script/Manual for Low-Intensity Group Check-in Call Form.” This form assesses changes in 
symptom severity during the past two weeks. The site staff pers on is directed to follow Telehealth crisis 
protocol, refer to Appendix 21, f or participants indicating “th oughts of death or suicidal ideation.” Site 
staff should also follow crisis procedures for any other proble ms identified during administration of the 
form where follow-up is needed.   For participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15- 21), high intensity stepped-care 
telehealth will consist of a CBT workbook with accompanying psy chotherapy by a Master’s- or doctoral-
level therapist delivered by telephone. Participants randomized  to EUC will receive survivorship 
resources (Appendix 20) and refe rral information for local ment al health providers. 
 
4. PARTICIPANT SELECTION 
 
4.1 Inclusion Criteria 
 
4.1.1.  Age ≥18 years 
 
4.1.2.  Score ≥10 on the GAD-7 and/or a score ≥8 on the PHQ-9, indicati ng clinically significant anxiety 
or depressive symptoms, respectively.  
 
4.1.3.  Past history of treated (ne wly diagnosed or recurrent)28,29 breast, colorectal, prostate, gynecologic 
(only uterine and cervical) cancers (Stage I, II, or III) or an y stage lymphoma (Hodgkin’s or non-
Hodgkin’s).   
 
4.1.4.  6-60 months post-treatment (surgery, chemotherapy, radiation th erapy, and/or maintenance 
therapies) for cancer. Time frame applies to most recent comple tion of treatment if participant 
had a cancer recurrence. It is acceptable to be on hormonal the rapies.  
 
4.1.5.  Participant resides in California, Georgia, Illinois, Kansas, M ichigan, Minnesota, Missouri, New 
Mexico, North Carolina, North D akota, South Carolina, Virginia,  Tennessee, or Wisconsin.  
 4.1.6.  Study-trained therapist in the s tate where the participant resi des.   
 
4.1.7.  Must be able to speak and understand English.  
 
4.1.8.  Must have access to a telephone. If a patient does not have acc ess to a phone or has difficulty 
paying for minutes for a mobile phone, the research team should  contact the Wake Forest 
investigators or site coordina tors to arrange for assistance.  
 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 12 of 43 
  
4.2 Exclusion Criteria 
 
4.2.1.  Current psychotherapy [regular  appointment(s) with a psycholog ist, counselor, or therapist within 
the last 30 days prior to randomization] 
 4.2.2.  Self-reported active alcohol or substance abuse within the las t 30 days 
 
4.2.3.  Past history of prostate cancer or non-Hodgkin’s lymphoma with  only active surveillance (i.e., no 
surgery, chemotherapy, or radiation therapy) 
 
4.2.4.  Progressive cancer (must be c onsidered no evidence of disease or stable)  
 
4.2.6.  Self-reported psychotic symptoms in the last 30 days prior to randomization (See item in 
Appendix 4: “Have you seen things that aren’t really there or h ave you heard voices when no one 
else was around within the last 30 days?”) 
 
4.2.7.  Active suicidal ideation with plan and intent 
 4.2.8.  Any change in psychotropic me dications within the last 30 days  (See Appendix 25) 
 4.2.9.  Hearing loss that would preclude participating in telephone se ssions (determined by brief hearing 
assessment administered by research staff at each NCORP compone nt). Individuals who can 
compensate for hearing loss through the use of a hearing device  or TDD phone, and through the 
use of such devices are able to communicate with the study ther apist by telephone, will be 
included. If the therapist cannot communicate with the particip ant by telephone, the participant 
will be excluded.  
 
4.2.10.  Failure/inability/unwillingness to  provide names and contact i nformation for two family members 
or friends to serve as emergency contacts during the course of the study 
 
4.3 Inclusion of Women and Minorities  
 
Both men and women (as applicable) and members of all races and  ethnic groups are eligible for this trial.  
 
  
 
    Females Males Total
 Ethnic       
Hispanic 8 7 15
Not Hispanic 40 35 75
ETHNIC 
TOTAL 48 42 90   Females Males Total
Racial       
Am Indian 1 0 1
Asian 2 1 3
Native 
Hawaiian 0 0 0
Black 6 9 15
White 39 32 71
RACIAL 
TOTAL 48 42 90
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 13 of 43 
 4.4 Recruitment and Retention Plan 
 Participants will be followed fo r 13 - 15 weeks. After the Week  13 visit (for participants in the 
intervention group, Week 13 measures should be completed after the intervention is finished and could be 
Weeks 13 – 15), the participant is no longer followed and data are no longer collected from the 
participant.  
NCORP sites will accrue to this t rial through the National Canc er Institute NCORP program. The WF 
NCORP RB will sponsor and administ er this trial. There will be a secure, password protected 
TELEHEALTH study website for the management of study participan ts including randomization, 
schedule of study visits and data entry of forms designated to be entered by site staff.  Data reports and 
documents will also be available.    
Potential participants may be r ecruited via (1) in-clinic scree ning during medical appointments; (2) 
identifying survivors through th e site cancer registry; (3) scr eening clinic charts; and (4) participant 
recruitment flyers (Support Document 5) and recruitment letters  (Support Document 4).  Local sites 
should check with their IRBs to determine if a  partial HIPAA w aiver is required for the review of 
participant medical records/charts.  Survivors will be approach ed in-person or by telephone by NCORP 
staff to ascertain interest a nd initial eligibility. We will tr ack numbers of survivors approached and 
screened, reasons for nonparticipation, and number randomized. All written materials will be at an 8
th 
grade reading level.  We expect to recruit minority participants through several stra tegies. (1) We will request review of our 
protocol and recruitment materials from the Wake Forest Baptist  Comprehensive Cancer Center Cancer 
Office of Cancer Health Equity (fo r whom Dr. Weaver serves as a n Assistant Director) and the Wake 
Forest NCORP Research Base (WF NC ORP RB) for suggestions to enh ance the appeal of our study to 
minority participants. (2) We will inform all Minority-Underser ved NCORPs affiliated with the WF 
NCORP RB in targeted states about the study and seek their feed back on how to enhance minority 
recruitment. Working with Dr. Glenn Lesser, PI of the WF NCORP RB, we will additionally reach out to 
Minority-based NCORPs not currently affiliated with Wake Forest , but with components/sub-components 
in targeted states and encourage them to participate in this st udy. (3) We will emphasize the importance 
of robust minority accrual at our  study kickoff meetings and pr ovide specific education and discussion 
about strategies to overcome ba rriers that underserved patients  may experience to study participation.   (4) 
We will monitor minority recruitment rates at our monthly WF NC ORP RB executive committee 
meetings and provide feedback to the NCORP sites via bimonthly study teleconference calls. Specifically, 
we will monitor the minority recruitment rate in conjunction wi th available data about the population of 
eligible patients at the site to identify sites that are potent ially under-performing with regard to minority 
accrual. Sites with strong minority recruitment will be asked t o share their experiences with other sites 
during these calls.   
Several elements of this trial were designed with retention in mind. First, the follow-up period is brief, 
with total study enrollment lasting only 13 – 15 weeks. Second,  the stepped-care telehealth group will 
receive weekly or biweekly (every two weeks) calls from researc h staff at NCORP components or 
therapists. We will send thank-y ou letters to the enhanced usua l care group following their assessments at 
baseline and 7 weeks (Support document 6). Finally, if a partic ipant does not have a telephone or is 
unable to purchase minutes for the ir mobile phone to participat e in the study intervention or assessments, 
the research team should contact the Wake Forest investigators or site coordinators to arrange for 
assistance.     
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 14 of 43 
  
5.  INTERVENTION PARAMETERS (RETEN TION, ADHERENCE, TREATMENT 
FIDELITY) 
 
5.1 Study retention 
 Study retention will be estimated by the proportion of particip ants who complete the Week 7 and 13 
visits.   
5.2 Adherence  
 Adherence will be recorded as th e percentage of therapy session s (for the high-intensity intervention 
group) or check-in calls (for the low-intensity intervention gr oup) each participant completes.  
 
5.3 Treatment Fidelity 
 For the purposes of the study, the rapists (who may or may not b e employees at NCORP component sites) 
are considered to be research the rapists and will contract (or subcontract) with the study to directly 
provide services for the research  grant.  As part of the contra ct, research therapists will be required to 
meet quality metrics including th e audiotaping of psychotherapy  sessions to ensure treatment fidelity.  All 
therapy sessions will be audiotaped , and 8% of psychotherapy se ssions (1 session per randomized 
participant) will be randomly sel ected for review (not live) by  Dr. Brenes using a measure of therapist 
adherence (Appendix 18) and competence developed and used by St anley and colleagues (Stanley et al., 
1996; Stanley et al., 2003).  This measure assesses both the co mpetence and adherence of the therapist in 
the delivery of the specific sk ills of the intervention (e.g., progressive muscle relaxa tion, problem solving, 
etc.) as well as an overall rating of therapist competence and adherence.  Data suggest high internal 
consistency (alpha = .91-.94) a nd greater variability in rating s attributed to clinicians (29%) than raters 
(9%), suggesting good reliability of the instruments (personal communication, Dr. Melinda Stanley; see 
Appendix 18 for a copy of this measure.)    Local site staff that are part of the research team and are res ponsible for making check-in calls with study 
participants will be audio-taped for adherence to study protoco l and competence.  All check-in calls will 
be audiotaped and 16% of calls ( 1 session per participant) will  be randomly selected for review (not live) 
by Dr. Danhauer using a measure o f adherence and competence dev eloped for this study (see Appendix 
19 for a copy of this measure.)  Dr. Danhauer will meet via tel ephone with the research staff whose 
ratings indicate difficulties in intervention delivery.   Therapists (CBT)/research staff (check-in calls) who do not dem onstrate competency (competency score 
< 6) will receive additional training until competency is demon strated.  Dr. Brenes will meet with 
therapists on a regular basis to discuss cases, review therapis t adherence and competence ratings, and 
answer questions regarding proto col administration. Any areas o f nonadherence will be reviewed, and the 
therapist will review any difficulties in intervention delivery .  
 
The primary purpose of the data collected from the audiotaped t herapy sessions and check-in calls is to 
identify research personnel who ar e not implementing the protoc ol/intervention with fidelity and to 
provide these personnel with add itional supervision and/or trai ning to improve protocol adherence.  This 
is a common approach used in clinical trials of psychotherapy a nd behavioral interventions. The study 
will not use aggregate data from the audiotaped sessions/calls as a feasibility/adoption metric.      
 
Study therapists will meet regular ly with Drs. Brenes or Danhau er for ongoing discussion of cases and 
study supervision.    
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 15 of 43 
  
5.4 Management of Study Risk  
 
The following procedures are in p lace to protect against possib le risks:  
 Participants who are at high risk for adverse outcomes (e.g., a ctive suicidal ideation with plan and intent, 
current psychosis) will be excl uded from the study. Participant s who do not meet study inclusion criteria 
will be provided with alternativ e referrals. If any participant  shows evidence of the need for immediate 
treatment (e.g., active psychosis, suicidal intent) at any time  during the consent, assessment, and 
treatment periods, the participant will be referred for immedia te psychiatric assistan ce (as specified in the 
Crisis Protocol, Appendix 21), a nd one of the co-PIs will be no tified. 
 The only risk of this study is that some individuals may find d iscussing their problems with others to be 
uncomfortable, embarrassing, and/ or stressful. This is expected  to be temporary. All study staff will be 
trained to deal with these situ ations, and every effort will be  made to address each participant’s concerns 
or problems in the most supportiv e, empathic, and therapeutic m anner. 
 
5.5.  Crisis Protocol 
 
If any participant indicates a significant worsening in anxiety  or depression scores (1 standard deviation 
increase (rounded to the nearest integer) on the GAD-7 (Change≥ 4)
75 or PHQ-9 (Change≥6)73 from 
baseline) or the participant e xpressed suicidal ideation on the  PHQ-9 (Question 9 score of >2), the 
computer software system will automatically generate an e-mail to the co-PIs and the Wake Forest School 
of Medicine Project Manager. The co-PIs or Project Manager will  follow up with staff (either the 
therapists for participants in the high-intensity stepped-care telehealth or site personnel for participants in 
the low-intensity stepped-care t elehealth or usual care arms) t o enact the Crisis Protocol and complete a 
Crisis Protocol Event Form.  During the course of a regularly s cheduled participant contact, it may 
become evident that there is a need for immediate evaluation. ( e.g., active suicidal ideation, active 
psychotic symptoms, disorienta tion). Staff will be instructed t o follow the Crisis Protocol and complete 
the Crisis Protocol Event Form . In both cases, the participant may be referred for psychiatric care by their 
primary care physician or by an emergency department physician.   
 Study staff will follow the step s outlined in the Crisis Protoc ol and participants will receive information 
about safety precautions and procedures to follow in the event of a crisis (i.e., the participant becomes 
imminently suicidal).  Because active suicidal ideation is an e xclusion criterion for the study, we 
anticipate that the risk of participants becoming suicidal duri ng the study will be minimal. Further, based 
on our prior studies, no participants randomized into the study  became imminently suicidal. All study 
staff (therapists, site staff) will receive training on the Cri sis Protocol and coping with participant distress 
that may be experienced during the consent, assessment and trea tment procedures.  In addition, sites will 
have regular study team meetings to discuss clinical issues.  D r. Brenes will review the status and 
progress of participants with the study therapists on a regular  (at least monthly) basis.  All participants 
will be contacted at Week 7 to assess the primary outcomes and depressive symptoms. Additionally, 
study therapists will attempt to reach participants who miss a session by calling the participant twice in a 
one-week period. If the therapist is unable to contact the part icipant by phone, the therapist will send the 
participant a letter by mail with a request that the participan t contact the therapist regarding interest in 
continuing the study sessions.  
 
5.5.1. Emergency Contacts 
 
As an additional safety precaution and part of the screening, p articipants will provide the names of two 
emergency contacts and their pho ne numbers. Study staff will co ntact the emergency contacts if needed 
during the administration of the Crisis Protocol or in any othe r emergency. If the Crisis Protocol is 
activated during a study session or contact and the participant  misses the next scheduled session, then the 
therapist will call the emerge ncy contacts immediately.    
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 16 of 43 
  
 6.   REGISTRATION 
 
6.1 Investigator and Research Associate Registration  with CTEP  
 
Food and Drug Administration (FDA)  regulations and National Can cer Institute (NCI) 
policy require all individuals contributing to NCI-sponsored tr ials to register and to renew 
their registration annually.  To register, all individuals must  obtain a Cancer Therapy 
Evaluation Program (CTEP) Identity and Access Management (IAM) account 
(https://ctepcore.nci.nih.gov/iam ).  In addition, persons with a registration type of 
Investigator (IVR), Non-Physician Investigator (NPIVR), or Asso ciate Plus (AP) must 
complete their annual registrati on using CTEP’s web-based Regis tration and Credential 
Repository (RCR) https://ctepcore.nci.nih.gov/rcr .  
RCR utilizes five person registration types. 
 IVR — MD, DO, or international equivalent; 
 NPIVR — advanced practice providers (e.g., NP or PA) or graduat e level 
researchers (e.g., PhD); 
 AP — clinical site staff (e.g., RN or CRA) with data entry acce ss to CTSU 
applications such as the Roster Update Management System [RUMS] , OPEN, 
Rave, acting as a primary site contact, or with consenting priv ileges; 
 Associate (A) — other clinical  site staff involved in the condu ct of NCI-sponsored 
trials; and 
 Associate Basic (AB) — individu als (e.g., pharmaceutical compan y employees) 
with limited access to NCI-supported systems. 
RCR requires the following registration documents: 
Documentation Required IVR NPIVR AP A AB 
FDA Form 1572 ✔ ✔ 
Financial Disclosure Form ✔ ✔ ✔   
       
NCI Biosketch (education, training, 
employment, license, and certification) ✔ ✔ ✔ 
GCP training ✔ ✔ ✔ 
Agent Shipment Form (if applicable) ✔ 
CV (optional) ✔ ✔ ✔ 
 
An active CTEP-IAM user account and appropriate RCR registratio n is required to access 
all CTEP and CTSU (Cancer Trials Support Unit) websites and app lications.  In addition, 
IVRs and NPIVRs must list all clin ical practice sites and Insti tutional Review Boards 
(IRBs) covering their practice sites on the FDA Form 1572 in RC R to allow the following: 
 Addition to a site roster 
 Assign the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN 
 Act as the site-protocol Principa l Investigator (PI) on the IRB  approval; and 
 Assign the Clinical Investigator (CI) role of the Delegation of  Tasks Log (DTL) 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 17 of 43 
      
In addition, all investigators act  as the Site-Protocol PI (inv estigator listed on the IRB 
approval), consenting/treating/drug shipment investigator in OP EN, or as the CI on the 
DTL must be rostered at the en rolling site with a participating  organization.  
 Additional information is located on the CTEP website at https://ctep.cancer.gov/investigatorResources/default.htm .  For questions, please contact 
the RCR Help Desk  by email at  RCRHelpDesk@nih.gov . 
 
6.2 Cancer Trials Support Unit Registration Procedures  
 
Protocol documents are found on  the CTSU website, but additiona l supplemental 
documents may be available on the Wake Forest NCORP Research Ba se website 
(https://wakencorp.phs.wakehealth.edu/dspLogin.cfm ). 
 
This study is supported by the NCI CTSU. 
 
IRB Approval:   
 
For CTEP and Division of Cancer Prevention (DCP) studies open t o the National Clinical Trials 
Network (NCTN) and NCI Community Oncology Research Program (NCO RP) Research Bases 
after March 1, 2019, all U.S.-based sites must be members of th e NCI Central Institutional 
Review Board (NCI CIRB). In addition, U.S.-based sites must acc ept the NCI CIRB review to 
activate new studies at the site a fter March 1, 2019. Local IRB  review will continue to be 
accepted for studies that are not reviewed by the CIRB, or if t he study was previously open at the 
site under the local IRB. International sites should continue t o submit Research Ethics Board 
(REB) approval to the CTSU Regulatory Office following country- specific regulations.  
 Sites participating with the NCI CIRB must submit the Study Spe cific Worksheet for Local 
Context (SSW) to the CIRB using IRBManager to indicate their in tent to open the study locally. 
The NCI CIRB’s approval of the SSW is automatically communicate d to the CTSU Regulatory 
Office, but sites are required to contact the CTSU Regulatory O ffice at 
CTSURegPref@ctsu.coccg.org  to establish site preferences for applying NCI CIRB approvals 
across their Signatory Network. S ite preferences can be set at the network or protocol level. 
Questions about establishing site  preferences can be addressed to the CTSU Regulatory Office by 
emailing the email address a bove or calling 1-888-651-CTSU (287 8). 
 
In addition, the Site-Protocol Pr incipal Investigator (PI) (i.e . the investigator on the IRB/REB 
approval) must meet the following criteria in order for the pro cessing of the IRB/REB approval 
record to be completed: 
 Holds an Active CTEP status; 
 Rostered at the site on the IRB/ REB approval (applies to US and  Canadian sites only) 
and on at least one participating roster; 
 If using NCI CIRB, rostered on the NCI CIRB Signatory record; 
 Includes the IRB number of the IRB providing approval in the Fo rm FDA 1572 in the 
RCR profile; and 
 Holds the appropriate CTEP registration type for the protocol.  
 
Additional Requirements 
 
Additional requirements to obtain an approved site registration  status include: 
 An active Federal Wide Assurance (FWA) number; 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 18 of 43 
  An active roster affiliation with  the Lead Protocol Organizatio n (LPO) or a Participating 
Organization (PO); and 
 Compliance with all protocol-s pecific requirements (PSRs). 
 6.3 Protocol Specific Requiremen ts for WF-30917CD Site Registra tion:  
 
 NCI CIRB approval – all participating sites must use the NCI CI RB as their IRB of record for 
WF-30917CD.   
 Confirmed study-trained therapist for the state in which the si te is located who has completed 
protocol specific training. 
 Site Open to Enrollment (SOTE) letter from WF NCORP RB, which i s provided to the site 
once all start-up activities have been completed. 
 
Practice Level Data Collection Form – The enrolling affiliate/s ub affiliate will complete 
the NCORP Practice Level Data Collection Form and submit it to the CTSU Regulatory 
Office using the Regulatory Submission Portal located in the Re gulatory section of the 
CTSU website. The form will collect various attributes about th e enrolling affiliate/sub 
affiliate. All of the questions on the form must be complete an d the distribution for the 
analytic cases question must equal 100%. (See form for directio ns.) The form must be 
received and complete for site reg istration approval in RSS. Th e Practice Level Data 
Collection Form requirement is submitted once for participation  on all NCORP Cancer 
Care Delivery (CCDR) trials, but will expire two years after it  is received. NCORP sites 
will need to resubmit the Practice Level Data Form to the CTSU in order to continue to 
enroll to CCDR trials.  
 
6.4 Submitting Regulatory Documents:  
 
Submit required forms and documents  to the CTSU Regulatory Office via the Regulatory 
Submission Portal on the CTSU website.   To access the Regulatory Submissi on Portal log in to the CTSU m embers’ website, go to the 
Regulatory section and select Regulatory Submission.    
 Institutions with patients waiting that are unable to use the R egulatory Submission Portal should 
alert the CTSU Regulatory Office immediately at 1-866-651-2878 in order to receive further 
instruction and support. 
 
6.5 Checking Your Site’s Registration Status: 
 
Site registration status may be verified on the CTSU member’s w ebsite.  
 
 Click on Regulatory at the top of the screen; 
 Click on Site Registration; and 
 Enter the sites 5-character CTEP Institution Code and click on Go. 
o Additional filters are available to sort by Protocol, Registrat ion Status, Protocol Status, 
and/or IRB Type 
 Note: The status shown only reflects institutional compliance w ith site registration requirements 
as outlined above. It does not refl ect compliance with protocol  requirements for individuals 
participating on the protocol or the enrolling investigator’s s tatus with the NCI or their affiliated 
networks. 
 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 19 of 43 
 7. CLINICAL EVALUATIONS AND PROCEDURES  
 
7.1 Intervention Description  
 Participants with moderate anxiet y and depressive symptoms will  be randomized to either the low-
intensity stepped-care telehealth  or the EUC control.  Particip ants with severe symptoms will be 
randomized to either the high-in tensity stepped-care telehealth  intervention or the EUC control. 
Therapists participating in the trial must meet the following r equirements: a Master’s or doctoral degree 
in counseling, marriage and family therapy, psychology, or soci al work; licensed as an independent 
mental health provider in Calif ornia, Georgia, Illinois, Kansas , Michigan, Minnesota, Missouri, New 
Mexico, North Carolina, North D akota, South Carolina, Virginia,  Tennessee, or Wisconsin; and 
experience with cognitive-behavio ral therapy.  Experience worki ng with oncology patients/survivors is 
preferred. Therapists will atte nd a 1.5-day training that will cover information on study design, anxiety 
and depression in cancer survivors, principles of cognitive-beh avioral therapy, delivery of the 
intervention, and use of the web -based data-entry system. NCORP  sites and/or components may nominate 
therapists for participation, but  are not required to identify a therapist to particip ate. The Wake Forest 
study team will identify a partic ipating therapist for each sta te. 
 
Low Intensity Stepped-care Tele health: The low-intensity steppe d-care telehealth group will consist of a 
self-guided CBT workbook (15 minutes daily to read and complete  exercises/homework) and biweekly 
(every two weeks) check-in calls (5-10 minutes) from an NCORP c omponent research staff person to 
assess changes in symptom severity /immediate need for psychiatr ic treatment and provide minimal 
support. Check-in calls are expect ed to be completed within +/-  2 days of the window specified in the 
Telehealth website; however, ch eck-in calls up to +/- 1 week of  the window are permitted. 
 
Consistent the ASCO guidelines,37 the Wake Forest NCORP Rese arch Base staff will mail a 
professionally-prepared and IRB- approved CBT workbook to partic ipants that focuses on different 
cognitive-behavioral techniques for managing anxiety, depressio n, and distress. CBT teaches people to 
monitor depressive and anxiety-pr oducing thoughts, modify these  thoughts, and modify behaviors that 
reinforce depression and anxiety. Chapters focus on the cogniti ve-behavioral model of depression and 
anxiety, relaxation techniques, cognitive restructuring, proble m solving, worry control, exposure, 
behavioral activation, and relapse prevention.   All participants receive 10 identical chapters.  To tailor the intervention to anxiety and depressive 
symptoms, participants are instr ucted to choose 2 chapters from  a menu of 5 chapters  (e.g. pain, more 
focused information on changing behavior related to anxiety or depression, etc.).  Workbook chapters 
target issues specific to cancer survivors, such as (a) fear of  recurrence (most commonly reported source 
of distress in survivors across different types of cancer);
8,9,13,24,38–48 (b) lasting effects of treatment on 
health, ongoing symptoms of fatigue and physiologic effects of cancer treatment;38,39,42,44,48–50 (c) late 
effects of cancer treatment (the possibility of developing othe r diseases);14,38,45 (d) concerns about 
reproductive ability and higher risk of cancer for their childr en;50,51 and (e) distress related to changes in 
body image and sexuality.14,41,45 These participants will also r eceive biweekly (every two weeks ) check-in 
calls from a research staff person at NCORP components to provi de support and assess symptom severity 
changes (Appendix 14). Participants with increased symptoms as indicated by 1 standard deviation 
increase and a total score of ≥15 on either the PHQ-9 or GAD-7 at Week 7 will be moved to the high-
intensity treatment or referred for more intensive psychiatric treatment (per the Crisis Protocol, see 
Appendix 21). If participants a re moved from the low intensity to high intensity treatment, the Participant 
Status Change Form should be com pleted (Appendix 23).  Analysis  will proceed as intent-to-treat with 
their initial stepped-care telehealth level; we do not anticipa te that many people will change from 
moderate to severe during the study.  
High Intensity Stepped-care Tele health: The high-intensity step ped-care telehealth group will consist of 
the CBT workbook (15 minutes daily to complete exercises/homewo rk), plus psychotherapy delivered by 
telephone with a licensed therapist (45 minute sessions weekly) . If participant is randomized to the High 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 20 of 43 
 Intensity Arm, the therapist will make at least one attempt to schedule the participant’s first therapy 
session within 2 weeks of the date of notification via email. 
 
Consistent with the ASCO guidelines,37 the Wake Forest NCORP Research Base staff will mail a 
professionally prepared and IRB approved CBT workbook to partic ipants and participants will have 12 
weekly therapy sessions with the s tudy therapist. The study the rapist will be a licensed mental health 
provider (e.g., licensed clinical  social worker, marriage and f amily therapist, licensed professional 
counselor, psychologist). Onsite or phone training is provided for all participating therapists. Training 
will include the use of the workbook, formal didactic presentat ions, readings, and role-plays. All study 
therapists will receive regular (at least monthly) study superv ision from Dr. Brenes . There will be at least 
one trained therapist for each st ate in the U.S. that has any p articipating sites. Each week, the participant 
will receive one 45-minute tele phone session and one workbook c hapter. The sessions will supplement 
the participant's understanding of anxiety, depression, and dis tress management techniques and include a 
review of the daily workbook exercises to assure understanding and maximize application in daily life. 
 Enhanced Usual Care. At the tim e of randomization, EUC particip ants will receive: (1) information about 
referrals/resources (Sample Resource Sheet) in their local area , including support groups and mental 
health providers (Appendix 20 and Support Document 9); (2) info rmation about written self-help 
resources (several readily availa ble published workbooks) for a nxiety and depressive  symptoms; and (3) a 
copy of the National Cancer Institute publication entitled “Fac ing Forward: Life after Cancer Treatment.” 
This publication can be viewed at the following web link: https://www.cancer.gov/publications/patient-
education/life-after-treatment.pdf.  Site staff should contact the NCORP Research Base site coordin ator 
who will ship a copy of the booklet to each EUC participant wit hin two weeks of randomization. It 
addresses the topics of follow up medical care, physical change s, body changes and intimacy, feelings, 
and social and work relationships. Upon completion of the Week 13 post-intervention assessment battery, 
the Wake Forest NCORP Research B ase staff will send a black and  white 2-sided copy of the CBT 
workbook to participants in EUC (same workbook provided to part icipants in the low-intensity and high-
intensity intervention groups). In addition, the EUC randomizat ion script can be used to help explain EUC 
to participants who are randomized to the EUC condition.  
 
7.2.  Schedule of Events 
 
NCORP site or component site sta ff is responsible for printing and mailing all study assessments and 
forms to be completed by the participant if forms are not compl eted by participants at the site.  A self-
addressed stamped envelope will be  provided by the local site f or the mailing of the signed consent form 
and all study assessment forms  to the local clinical site.  Par ticipants can also opt to scan and email or text 
the signed consent form; however, participants cannot opt to sc an and email or text study assessment 
forms.  It is anticipated that there will be <10 participants p er state which will keep  site costs reasonable.  
Study assessment and data collection information are provided i n subsequent sections. 
 
All participants will complete pre- and post-intervention asses sments with primary outcomes additionally 
assessed at mid-intervention (Week  7).  The PHQ-9 and GAD-7 may  be administered by telephone. 
 Participants receiving the high-intensity stepped-care teleheal th intervention will be reminded during their 
last session that they will receive a post-intervention questio nnaire packet via mail. Participants in the 
EUC group will receive an e-mail or telephone reminder (per the ir preference) that they will receive 
questionnaire packets via mail. If study questionnaires are not  received within 2 weeks of the documented 
mail date, the NCORP site research staff will contact participa nts via telephone or email. If participants 
cannot be reached within 3 days by  phone or email, the NCORP si te research staff will mail another 
questionnaire packet. If there is still no response within two weeks of mailing the additional set of post-
intervention questionnaires, participants will be contacted via  phone and offered the opportunity to 
complete the post-intervention questionnaires by phone.  
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 21 of 43 
 7.3 Baseline Testing/Pre-Study Evaluation 
 
7.3.1. Rationale for Multi-Step Consent Process   
We anticipate that a large pr oportion of the potential particip ants whom we screen may be 
ineligible for the study. To mi nimize burden and be most consid erate of participants’ time, we 
plan to implement a multi-step  consent process as described bel ow. Essentially, we will describe 
as much information as needed to obtain critical screening info rmation and only fully explain the 
entire study to participants who meet eligibility criteria. In brief, we plan to proceed as follows 
(see schema below): (1) Prior to the pre-screening visit, the p otential participant’s name, contact 
information, demographics and chart information for eligibility  criteria will be collected on a Pre-
Visit Form (Appendix 2) that w ill be reviewed with potential pa rticipants during the pre-
screening visit; (2) Brief pre-screening visit with a waiver of  documentation of informed consent, 
a 3-item depression/anxiety screening, an item to determine ade quate hearing ability, determine if 
they have access to a phone, unders tand English and review of t he previously collected contact 
information, demographics and basic information about cancer di agnosis and treatment 
(enrollment criteria); (3) Full study screening with the Abbrev iated Verbal Consent to include the 
full PHQ-9 and GAD-7. . The abbrev iated consent will explain th e screening process without 
details of the full study; and (4) Full informed consent will t hen take place for any potential 
participants who meet all eligibility criteria in the first two  steps described here. If the participant 
is present in person, all of th ese steps may be completed in th e same visit.  
 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 22 of 43 
  
Schema of Three-Step Consent Process 
  
 

   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 23 of 43 
 7.3.2.  Pre-Visit Form 
 
For potential participants who ar e eligible to be contacted for  the Pre-Screening visit, the Pre 
Visit Form will be completed on paper prior to the Pre-Screenin g visit to streamline the multistep 
screening process.  This form includes their full name, contact  information (phone number, 
address), demographics and chart information (eligibility crite ria – type of cancer, month/year of 
diagnosis, cancer stage at time of  diagnosis, time of last trea tment, date of birth, residency zip 
code).  Sites should track Pre-Vis it Form completion internally .  This information will not be 
entered into the Telehealth webs ite at the time this informatio n is collected.  It is important to 
retain contact information on the Pre-Visit Form so that sites can verify contact information 
during the Pre-Screening visit.  This step is important when re cruiting for a study of depression 
and anxiety as study staff may encounter someone who is suicida l and will need to take steps to 
ensure safety.   
 7.3.3. Pre-Screening   
 
Referred participants will be inv ited to complete pre-screening  for this study.  If site staff are 
unable to make the initial pre-screening invite contact after 5  attempts, the referred participant 
will be considered a passive refusal and will no longer be cont acted by site staff. If pre-screening 
is scheduled for a later date and the referred participant cann ot be re-contacted after 5 attempts, 
the referred participant will be  considered a passive refusal a nd will no longer be contacted by 
site staff.  For referred partic ipants who are considered a pas sive refusal, site staff will be asked to 
enter only race, ethnicity, cancer type, cancer stage, year of birth, and  contact attempts into the 
Telehealth website. 
 
Participants who accept the study invite will be asked to provi de a verbal waiver of 
documentation of informed consent to complete pre-screening cal l or visit.  If a participant 
provides verbal consent, the Pre-Visit Form will be reviewed wi th participants to confirm contact 
information, demographics and chart information (eligibility cr iteria – type of cancer, month/year 
of diagnosis, cancer stage at ti me of diagnosis, time of last t reatment, date of birth, residency zip 
code).  Participants will also be asked to complete the PHQ-2, 1 anxiety question, and additional 
questions to further pre-screen for additional eligibility crit eria including an item to determine 
adequate hearing ability (please re fer to the next paragraph fo r additional hearing ability 
information), telephone access and English language fluency.  P re-Screening information will be 
collected on paper forms.  This information will not be entered  into the Telehealth website at the 
time Pre-Screening information is collected.  
To determine adequate hearing ab ility, the participant is asked  to repeat the phrase, “I have a cat 
so all I need is a dog.”  If the participant is able to repeat,  staff will continue with screening.  If 
the participant is unable to repeat after a second attempt or i f staff thinks hearing is a problem, the 
participant is ineligible and w ill not be screened further.  Pa rticipants with a circumstance that 
could affect the ability to hear at the time of the call (illne ss, hearing aid problem, in process of 
obtaining hearing aid, etc.) can reschedule.  It is suggested t hat participants who are screened at 
the site call the site staff from their cell phone or other sit e/clinic phone. 
 
If someone declines pre-screening or is ineligible after pre-sc reening, no Protected Health 
Information (PHI) will be entered  into the Telehealth website.  For individuals who do not 
proceed to full screening, s taff will be asked to enter only race, ethnicity, cancer type, cancer 
stage, and year of birth from the Pre-Visit Form into the Teleh ealth website.  A PID will be 
assigned at this time.  All information collected on the Pre-Sc reen Form will be entered in the 
Telehealth website. 
 
 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 24 of 43 
 If a participant meets the elig ibility criteria based on respon ses to the questions and scores ≥ 2 on 
the PHQ-2 or ≥ 1 on the anxiet y question, they will be invited to participate in the full screening 
assessment to determine eligibilit y for the study. In order to complete the full screening, sites will 
administer the abbreviated verbal consent.  It is recommended t hat the screening immediately 
follow the pre-screening; however, there is no time limit betwe en the Pre-Screening and 
Screening visits.  For those who agree to  the abbreviated verb al consent for full screening, all 
data from the Pre-Visit Form and Pre-Screening will be entered into the Telehealth website.  A 
PID will be assigned at this time. 
 
7.3.4. Full Screening 
 
If a participant meets the elig ibility criteria on the pre-scre en, the participant will be asked to 
complete the Abbreviated Verbal  Consent for full screening. Onc e a participant has agreed to  the 
abbreviated verbal  consent, emergency contact information will  be collected and the PHQ-9 and 
GAD-7 will be administered. If th e participant is eligible base d on the scoring of the PHQ-9 and 
GAD-7, then additional screening questions will be administered .  
  
 The PHQ-9 is a nine-item self-re port measure used for screening , diagnosing, monitoring and 
measuring the severity of depression that incorporates DSM-IV d epression diagnostic criteria. 
A score ≥ 8 indicates moderate depressive symptoms, and a score  ≥15 suggests severe 
depressive symptoms 
 
 The GAD-7 is a seven-item self-report measure that incorporates  DSM-IV symptoms for 
generalized anxiety disorder. A score ≥ 10 indicates moderate a nxiety symptoms, and a score 
≥ 15 suggests severe symptoms. 
 
 
All pre-screening and/or screening steps may be completed in on e visit or phone call. If done in 
person, the anxiety question, P HQ-2, PHQ-9 and GAD-7 are to be interviewer administered, and 
there should not be any missing data on these forms.  
 Subjects who agree to the  abbreviated verbal consent and do no t complete the full screening at 
this time will be  contacted up to 5 more times by the site sta ff.  After 5 contact attempts the 
subject will be considered lost to follow-up and will be consid ered a screen fail, unless the 
subjects re-contacts the site.  Site staff will enter any scree ning information collected in the 
Telehealth website.    Randomization must happen within  30 days of screening. If more than 30 days has passed, the 
full screening assessment shoul d be re-administered. 
 
7.3.5. Full Informed Consent 
 
If the participant is eligible b ased on the screening visit res ponses and is willing to participate, the 
full informed consent for study pa rticipation should be adminis tered. 
 If a participant is not eligible  or declines study participatio n at screening, site staff will enter 
screening information in the Tel ehealth website up to the point  the participant was no longer 
eligible or declined, and no fur ther information will be collec ted. 
 7.4  Baseline Testing
 
 
If full informed consent was admi nistered by phone, the site mu st receive the signed full informed 
consent prior to initiating base line study activities. Baseline  Interviewer-Administered Measures and 
Chart Review must be administere d and completed by site staff.  Baseline Self-Administered Measures 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 25 of 43 
 may be completed by the particip ant at the site or site staff m ay choose to mail base line self-administered 
measures to the participant  with a request that they be return ed as soon as possible and within two weeks 
(see Section 7.2).  If the self-administered measures are maile d to a participant, site staff may call the 
participant to collect self-ad ministered baseline responses by phone. Randomization must happen after 
baseline assessments but within 3 0 days of screening.  Replacem ent packets can be mailed or emailed at 
participant request. The sites must receive the following self- administered completed forms from the 
participant prior to enrolling a nd randomizing the participant.   
 
Self-Administered Measures (Appendix 5a/5b): 
 
 Demographics and Health Behaviors 
 Fear of Recurrence Inventory--Severity Subscale 
 Insomnia Severity Index 
 PROMIS – Fatigue Scale – Short Form 8a 
 SF–36 Health Survey 
 Impact of Events Scale–Revised 
 Satisfaction with Medical/Mental Health services 
 
Interviewer Administered Measures and Chart Review (Appendix 6) : 
 
NCORP component research staff will administer the following fo rms (see Appendices) by telephone (or 
in person if participant is in c linic) and enter the data on th e study website as the data are collected.  
These forms are to be interviewe r-administered whether the cont act is by telephone or in person.  
The PHQ-9 and GAD-7 should have no missing data.    
 PHQ-9 (administer only if it has been >30 days sin ce screening to reassess eligibilit y) 
 GAD-7 (administer only if it has been >30 days sin ce screening to reassess eligibilit y) 
 Charlson Comorbidity Index  
 Cornell Services Index 
 Current Medication Use 
 
Chart Review: 
 Initial Cancer Diagnosis and Treatment Form 
 Additional Malignancy Diagnosis and Treatment Form 
 Cancer Relapse/Recurrence Form 
 
7.5 Participant Enrollment and Randomization 
 The electronic participant enrollment form (Appendix 7) will be  completed on the day of 
randomization in the Telehealth  study website.  The subject sho uld not be randomized and 
enrollment form completed until the subject is ready to start t he intervention.  Review the 
Appendix 5a/5b (Baseline Self-Re port Measures) for completeness  before randomization. Once 
the participant is randomized, t he study timeline begins.  A pa rticipant will not be considered 
enrolled if they are not randomized to a study arm. Following r andomization, the Randomization 
Form should be completed (Appendix 8). 
 
7.6 Evaluation During Study Intervention 
 
Weeks 1-12:  
 High Intensity Week 1/Low Intensity Week 2 :  The Expectancy Rating Scale and 
instructions (Appendix 10a/b) w ill only be mailed to participan ts who are randomized to either 
the Low Intensity or the High Intensity intervention groups. Pa rticipants are to complete this 
Expectancy Rating Scale after th ey have completed Chapter 1 of the Cognitive Behavior 
Therapy Workbook. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 26 of 43 
  Enhanced Usual Care participants will not be mailed the Expecta ncy Rating Letter or Scale.  
 Enhanced Usual Care participan ts will be mailed a “Thank You” l etter at baseline (Support 
Document 6).  
 Stepped-Care Telehealth (High In tensity) Progress Notes (Append ix 16)/Session Information 
Form (session completed Y/N) (En tered by therapist or NCORP com ponent research staff on 
study website within 48 hours of therapy or check-in sessions) 
 Telephone Script/Manual for Low Intensity Bi-Weekly (every two weeks) Check-In Call Form 
(Appendix 14).  
 Implementation costs (tracking logs) (Appendix 24)  
 
Week 7: (visit must be completed between Week 6 and Week 11)  
NCORP component research staff will administer the following mi d-intervention assessments by telephone 
and enter in the study website (Appendix 11).   
 PHQ-9   
 GAD-7  
 Current Medication Use (Update)  
 Adverse Event Ascertainment Form  
 Mid-intervention letter mailed to Enhanced Usual Care participa nts only (Support Document 
6). 
 
7.7 Evaluation at Completion of Study Intervention – Week 13 (c ould occur weeks 13-15 only 
for High Intensity Participants):  (visit must be completed between Week 12 and Week 15)  
 
Self-Administered Measures (Appendix 12a/b):  
 
Participants will be mailed the following self-report post-inte rvention measures with a request that they 
be returned within two weeks.  
 Fear of Recurrence Inventory--Severity Subscale 
 Insomnia Severity Index 
 PROMIS Fatigue Scale- Short Form 8a 
 SF-36 Health Survey 
 Impact of Events Scale – Revised 
 Client Satisfaction Questionnaire 
 Working Alliance Inventory-Partic ipant (high-intensity particip ants only) 
 Expectancy Rating Scale (low int ensity and high intensity parti cipants only) 
 
Interviewer Administered Measures and Chart Review (Appendix 13 ): 
 
NCORP component research staff will administer the following po st-intervention measures by telephone 
and enter on the study website:   
 PHQ-9 
 GAD-7 
 Cornell Services Index 
 Current Medication Use (Update) 
 Adverse Event Ascertainment Form 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 27 of 43 
  
Chart Review: 
 Cancer Relapse/Recurrence Form 
 
After all therapy sessions with each participant have been comp leted, the therapist will complete the 
Working Alliance Inventory-Therapist form (Appendix 17). The Wo rking Alliance Inventory is a process 
measure to evaluate the potential impact of the telehealth inte rvention on the therapist-participant 
relationship. 
 
7.8 End of Study 
 
Upon completion of study visits, the Participant Completion Let ter (Support Document 3) and the 
Resource Sheet (Support Document 9) will be mailed to participa nts in the Low Intensity and High 
Intensity groups. 
 
 
7.9 Methods for Clinical Procedures 
 
The Study Parameter Table (below) indicates the timing, mode of  administration, and person who 
administers every aspect of the study. 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 28 of 43 
 Study Parameter Table 
 
Recruitment/             
Chart Review 
Pre-Screen 
Verbal Consent 
Full Screen 
Full Informed  
Consent 
Baseline 
Enrollment/ 
Randomization (wk0) 
Weeks 1-13 
Post Week 13 
Arm Wk1 or 2 
W7 
W13 
NCORP Component Site Staff Responsibility 
Mail Recruitment Documentation*  As 
needed          --- 
Pre-Visit Form (Appx 2) X            --- 
Pre-Screening Form (Appx 3)*  Xa          --- 
Abbreviated Verbal Consent   Xa         --- 
Screening Form (Appx 4)*    Xa        --- 
Full Informed Consent     Xa       --- 
Baseline Self-Report Letter and Measures (Appxs 5a+b)*      Xa      --- 
Baseline Interviewer-Administered Measures and Chart 
Review (Appx 6)*       Xa      --- 
Letter to Ineligible Participants (SD 2)  As Needed        --- 
Enrollment Form (Appx 7)       X      --- 
Randomization Form (Appx 8)       Xb     --- 
EUC Randomization*       X   X    EUC 
Expectancy Rating Scale and Letter44,45,64 (Appxs 10a+b)        X     LISC/ 
HISC
Low Intensity Check-In Call Form (Appx 14)        Biweekly 
(wks 2/4/6/8/10/12) LISC 
Upload audio recordings        Biweekly 
(wks 2/4/6/8/10/12) LISC 
Week 7 Mid-Assessment In terviewer-Administered 
Measures (Appx 11)*         X    All 
Week 13 Self-Report Letter and Measures (Appxs 12a+b)*          X   All 
Week 13 Interviewer-Administered Measures (Appx 13)*          Xc  All 
Participant Completion Letter (S D 3)/Resource Sheet (SD 9)           X  LISC/ 
HISC
Participant Change Status Form (Appx 23)        As Needed All 
Adverse Event Form (Appx 22)  As Needed  All 
Crisis Protocol Event Form (Appx 21)  As Needed  All 
Tracking Log (Appx 24)  To be completed for each attempted contact and actual contact  All 
Wake Forest Research Base Responsibility 
EUC Randomization*       X     EUC 
Investigator adherence rating forms (Appx 18 and 19)*        As needed  LISC/ 
HISC 
Mail Recorder       As 
needed     LISC/ 
HISC 
Mail CBT Booklet       X      LISC/ 
HISC 
Mail CBT Booklet           X  EUC 
Study Therapist Responsibility 
Weekly Therapist activities (Appxs  15-17) recordings*        We ekly (wks 1-13)   HISC 
Tracking log  To be completed for each attempted contact and actual contact  HISC 
Abbreviations: Appx=Appendix, EUC=Enhanced Usual Care, HISC=High-Intensity Stepped-Care Arm, LISC=Low-Intensity Stepped-Care Ar m  
* See appendix 26 for details 
a If participant is being seen in person, all of these steps can occur during one appointment  
b Randomization should happen within 30 days of the full screen. If not, full screen (appx 4) will need to be re-administered 
c For participants in the HISC arm, week 13 measures should be comp leted after the intervention is finished (could be weeks 13-15 ) 
Note:  Regarding potential participant burden, estimated times to com plete study measures are as follows: pre-screen (5-10 minutes);  screen (up 
to 20 minutes); participant measures at baseline and Week 13 (3 0-60 minutes); participant meas ures at Week 7 (5 minutes) 
Note:  See the Telehealth website for  specific windows of when data s hould be collected post-randomi zation for each participant. The  PHQ-9 and 
GAD-7 must be entered into the T elehealth website within 48 hou rs of administration. All other assessments should be entered w ithin 14 days of 
the date assessments are completed unless otherwise specified. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 29 of 43 
  
 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION  
8.1 Primary Endpoint 
 
To determine study feasibility, r ecruitment, accrual, retention , and adherence rates will be calculated as 
follows: 
 Recruitment . To determine recruitment rate, we will track number of indivi duals who met all eligibility 
criteria and percent who agree to participate.   Accrual . Accrual rates will be calculated by calculating the mean numb er of participants recruited per 
month.  
 Retention . Study retention will be estimated by the proportion of partic ipants who complete the Week 13 
visit. Drop-out is defined as 100% minus the dropout %.  
Adherence . Intervention adherence will b e estimated as the mean percenta ge of therapy (high-intensity 
intervention) or check-in (low-intensity intervention) sessions  each participant completes. 
 The Working Alliance Inventory will be summarized with descript ive statistics to describe the therapist-
participant relationship as a process measure  8.2 Secondary Endpoints 
 
8.2.1. Depression and Anxiety Measures 
 
The PHQ-9  is a self-report measure of DSM-IV symptoms of Major Depressiv e Disorder.  
Participants rate how often they have experienced nine symptoms  over the past 2 weeks on a 
scale of 0 (not at all) to 3 (nearly every day). Responses are summed, with higher scores 
indicating greater depressive symptomatology. It has demonstrat ed good reliability and validity. 
The traditional cutoff for the P HQ-9 is a score ≥10.  However, ASCO guidelines recommend 
using a score ≥8, based on a study of cancer outpatients76  and a meta-analysis of use of the PHQ-
9 for identifying depressi on in cancer patients.77  
 
The GAD-753 is a self-report measure of DSM-IV symptoms of GAD.  Participa nts rate 7 
questions on a scale of 0 (not at all) to 3 (nearly every day);  one additional question assesses the 
interference of these symptoms with functioning.  The first 7 q uestions are summed to create a 
total score.  It has been validat ed for use in the general popu lation70 and in primary care.53  The 
GAD-7 has demonstrated good sensitivity (89%) and specificity ( 82%) in identifying GAD 
diagnoses when using a cut point of 10.53 It also has good internal c onsistency (alphas = 0.89-
0.92) and test-retest reliability (intraclass correlation = .83 ).53,70  
 
8.2.2. Quality of Life and Symptom Measures: 
 
The Fear of Cancer Recurrence Inventory55 (FCRI; severity subscale) will be used to measure 
self-reported fear of recurrence. This 9-item subscale measures  the presence and severity of the 
intrusive thoughts or images asso ciated with the fear of recurr ence, and it can be used separately 
as a short form of the 42-item FCRI for the brief screening of fear of cancer recurrence. The 
measure is widely used and has strong reliability and validity (Cronbach’s α=0.75). 
 
The Insomnia Severity Index (ISI)56 is 7-item self-report measure of type and severity of 
insomnia symptoms, including pro blems with sleep onset, sleep m aintenance, or early morning 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 30 of 43 
 awakening; satisfaction with cu rrent sleep pattern; interferenc e with daily functioning; noticing 
impairment attributed to sleep p roblems; and level of concern o r distress caused by the sleep 
problem.  Responses are summed, with higher scores indicating g reater sleep impairment.  It has 
demonstrated reliability and validity in screening primary care  patients for insomnia.71 
 
The PROMIS Fatigue Short Form72 is a measure of the experience of fatigue and the impact of 
fatigue on activities across multiple domains.  Seven items are  rated on a scale of 1(never) to 5 
(always) based on how often it was experienced over the last 7 days.  
 The SF-36
59 is a self-report measure of qua lity of life consisting of 36 it ems that form 8 
subscales:  physical functioning, r ole limitations due to physi cal health problems, role limitations 
due to emotional health problem s, social functioning, freedom f rom pain, energy or fatigue, 
emotional well-being, and general health perceptions.  These 8 subscales are also combined into 
two domains: the Physical Component Summary (PCS) and the Menta l Component Summary 
(MCS).  All of these scales range from 0 (maximum impairment) t o 100 (no impairment). All 
scales range from 0 (maximum impairment) to 100 (no impairment) .  It has demonstrated good 
internal validity and construct validity.60,61  
 
The Impact of Events Scale – Revised (IES-R)62,63 is a 22-item self-report measure of cancer-
related distress. It is one of the most widely used measures of  event-specific distress. The IES-R 
assesses the frequency with which respondents experience intrus ive thoughts, avoidant behaviors, 
and autonomic arousal specific to one’s thoughts and feelings a bout cancer over the past week.  
 8.2.3. Health Care Utilization 
 
The Cornell Services Index
66 is a structured interview that assesses the frequency of use o f 
medical outpatient visits, psychia tric and psychotherapeutic vi sits, and intensive services such as 
hospitalizations, emergency room  visits, and home health visits .  The services assessed in the 
Cornell Services Index are aggregated into outpatient psychiatr ic or psychological services, 
outpatient medical services, professional support services, and  intensive services.   
 
8.2.4. Implementation Costs 
 
Tracking logs will measure the time spent in intervention-relat ed activities such as bi-weekly 
check-in phone calls and therapy sessions with participants in stepped care, related to 
implementation. Tracking logs s hould be entered within 1-2 days  of intervention-related 
activities; however, sites have up to 30 days to enter this inf ormation. NCORP Research Base 
Staff will keep an internal reco rd of staff meetings, phone cha rges, mailing and printing costs and 
therapist training.   
 8.3 Off-Study Criteria 
 
Participants may go ‘off-study’ for the following reasons: the protocol intervention and any protocol-
required follow-up period is completed, serious adverse event, lost to follow-up, withdraw consent, PI 
removes from study, or death. 
 For subjects who are enrolled, site staff must contact the subj ect at the next study visit with at least 5 
attempts.  After 5 documented contact attempts the subject will  be considered lost to follow-up.  Site staff 
must complete a Participant Status Change Form (Appendix 23) in  the Telehealth website. 
 8.4 Study Termination 
 
NCI/DCCPS as the study sponsor or the Wake Forest NCORP Researc h Base has the right to discontinue 
the study at any time.  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 31 of 43 
  
 
 
9. CORRELATIVE/SPECIAL STUDIES- N/A 
 10. SPECIMEN MANAGEMENT- N/A 
 
11. REPORTING ADVERSE AND SERIOUS ADVERSE EVENTS 
 
11.1 Reportable Adverse Events  
An adverse event (AE) is define d as any untoward or unfavorable  medical occurrence in a human subject, 
including any clinically significant abnormal sign (for example , abnormal physical exam or laboratory 
finding), symptom, or disease, temporally associated with the s ubject’s participation in the research, 
whether or not considered related to the subject’s participatio n in the research. The burden of collecting 
and reporting data on every possible AE is excessive and theref ore, in Telehealth, sites will report all 
serious adverse events (SAEs) described in Section 11.2 and sel ected AEs listed in Section 11.3.  
 
SAEs and AEs will be ascertained  by site staff for all particip ants at Weeks 7 and 13. Telehealth staff will 
administer the Adverse Event Ascertainment Form (Appendix 22) t o specifically query participants about 
safety events at weeks 7 and 13.   In addition, adverse events may also be reported to study staff 
spontaneously through telephone calls, emails or other correspo ndence.  In addition to local reporting 
requirements, all SAEs and selected AEs will be recorded on the  Adverse Event Form by clinic staff.  
SAEs occurring during the study should also be reported for all  participants to CTEP-AERS (see section 
below).   AEs will be assessed according to  the grade associated with the  CTCAE term. AEs that do not have a 
corresponding CTCAE term will be  assessed according to the gene ral guidelines for grading used in the 
CTCAE v5.0.. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm  
 
11.2  Serious Adverse Events 
 
Definition: Regulations at 21 CFR §312.32 (re vised April 1, 2014) define an  SAE as any untoward 
medical occurrence that at any dose or intervention level has o ne or more of the following outcomes: 
 A Serious Adverse Event (SAEs) is defined if it results in ANY of the following outcomes: 
 Death 
 Life-threatening  
 Results in inpatient hospitalization or prolongation of existin g hospitalization for ≥ 24hours 
 A persistent or significant incapacity or substantial disruptio n of the ability to conduct normal 
life functions 
 A congenital anomaly/birth defect 
 Important Medical Event (IME) that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon medi cal judgment, they may 
jeopardize the patient or subject and may require medical or su rgical intervention to prevent 
one of the outcomes listed in this definition. (FDA, 21 CFR 312 .32; ICH E2A and ICH E6). 
 
Reporting Requirements for above Study Descriptions: 
 All unexpected hospitalizations regardless of grade 
 All Grade 5 toxicities (deaths-expected and unexpected) 
 All unexpected Grade 4 toxicities 
 All additional reporting requirem ents as outlined in the protoc ol 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 32 of 43 
  
Serious adverse events as describ ed above must be reported on t he Telehealth Adverse Event Form and 
also be reported to CTEP-AERS: 
 
CTEP-AERS (Research Base Data Management) reporting timelines a re defined as: 
 Deaths or life threatening events  (Grades 4-5): 24-Hour; 5 Cale ndar Days - The SAE must 
initially be reported via CTEP-AERS within 24 hours of learning  of the SAE, followed by a 
complete expedited report within  5 calendar days of the initial  24-hour report. 
 Hospitalizations, disabling, important medical events (IME) tha t may not result in death, be 
life threatening, or require hospitalization (Grade3) and study  specific adverse events:  10 
Calendar Days - A complete expe dited report on the SAE must be submitted within 10 
calendar days of learning of the SAE. 
 
11.3 Selected Adverse Events 
 A select list of adverse events i nclude suicide attempts, psych osis, worsening anxiety, worsening 
depression, and suicidal ideati on, should be reported as an adv erse event, regardless of whether they 
resulted in an ER visit or hospitalization.  
 
11.3.1. Definition of Worsening Anxiety or Depression 
 
An adverse event form should be completed for any participant w ho indicates a significant 
worsening in anxiety or depressi on scores (1 standard deviation  increase (rounded to the nearest 
integer) on the GAD-7 (Change≥4)75 or PHQ-9 (Change≥6)73,74,51 from baseline). The computer 
software system will automatically  generate an e-mail to the co -PIs and the project manager. If 
there is a need for immediate tr eatment (e.g., active suicidal ideation, active psychotic symptoms, 
disorientation, and active substa nce abuse) at any point in tim e, staff persons will notify the co-
PIs.  In both cases, the participan t may be referred for psychi atric care.   
 
12. STUDY MONITORING 
 
12.1 Data Management 
 
The Enrollment Form should be completed on-line  at randomizati on.  Data will be entered 
directly into the study website.  The PHQ-9 and GAD-7 must be e ntered into the Telehealth 
website within 48 hours of being administered.  The Crisis Prot ocol form (Appendix 21) must be 
entered into the Telehealth website at the time the form is com pleted with the participant.  Refer to 
Section 11 for submitting the Adverse Event form.  All other as sessments must be completed 
within the designated study vis it windows then data entered int o the Telehealth website by 
designated site staff or designate d study therapist within 14 d ays from the date assessments are 
completed.    12.2 Case Report Forms 
 
Participant data will be collected using protocol-specific case  report forms (CRF).  
 
12.3 Source Documents 
 The sources of research material will include information provi ded through participant interviews, 
intervention sessions, and self-report questionnaires specifica lly for this research study. A number of 
steps will be taken to ensure  the confidentiality of research d ata collected during the study. The study will 
obtain a Certificate of Confidentiality which prevents research ers from being forced to disclose 
identifying information by certa in legal proceedings. All forms  will be stored in locked file cabinets. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 33 of 43 
 Names will be removed from all forms and records and replaced w ith participant numbers. Recorded 
sessions will be erased upon completion of data collection. Inf ormation stored in the computer will be 
password protected. Only members of the investigative team will  have access to any participant 
information and data. The iden tities of participants will not b e revealed in publications and presentations 
of any results from this project . Procedures specified in the c onsent form are consistent with HIPAA 
regulations. All investigators have completed NIH-required trai ning in human subjects protection. 
 
An investigator and other designated staff are required to prep are and maintain adequate and accurate 
documentation that records all ob servations and other data pert inent to the investigation for each 
individual participating in the  study. All data recorded in the  research record (including data recorded on 
CRFs) must originate in the par ticipant’s medical record, study  record, or other official document sources. 
 Source documents substantiate CRF  information. All participant case records (e.g., flo w sheets, clinical 
records, physician notes, corr espondence) must adhere to the fo llowing standards: 
 
 Clearly labeled in accordance with HIPAA practices so that they  can be associated with a 
particular participant identification number (PID); 
 Legibly written in ink; 
 Signed and dated in a real time basis by health care practition er evaluating or treating the 
participant; and 
 Correction liquid or tape must not be used in source documents or on CRFs. 
 Corrections are made by drawing a single line through the error . Do not obliterate the original 
entry. Insert the correct information, initial, and date the en try. 
 12.4 Data and Safety Monitoring Plan
 
 
The Comprehensive Cancer Center Data Safety Monitoring Board me ets every six months to review all 
phase II and phase III protocols. The Board includes members de monstrating experience and expertise in 
oncology, biological sciences, b iostatistics, pastoral care/cou nseling, and ethics. The members of this 
committee as well as the organization statistician will oversee  the safety monitoring of the study, ensure 
that the privacy of all participants in the study is protected and ensure that participants' interests are 
primary, that is, above the interests of the scientific investi gation. Adverse events will be elicited by study 
staff during assessments and check-in calls for the EUC group a nd by the study therapists during each 
session. Information about any adverse events will be presented . By examining this information, the data 
and safety monitoring team will keep abreast of critical issues  regarding recruitment and data integrity. 
Reports of all DSMB meetings a nd recommendations will be provid ed to the NCI and WFUSM IRB. 
 
12.5 Sponsor or FDA Monitoring 
 
The NCI, DCCPS (or their design ee)  may audit various aspects o f the study. This auditor will be given 
access to facilities, databases, supp lies and records to review  and verify data pertinent to the study. This 
protocol does not include pharm aceuticals or require FDA monito ring.  
 
12.6 Record Retention 
 
Clinical records for all partic ipants, including CRFs, all sour ce documentation (containing evidence to 
study eligibility, history and physical findings, laboratory da ta, results of consultations, etc.), as well as 
IRB records and other regulatory  documentation will be retained  by the Investigator in a secure storage 
facility in compliance with Health Insurance Portability and Ac countability Act (HIPAA), Office of 
Human Research Protections (OHRP) , Food and Drug Administration  (FDA) regulations and guidances, 
and NCI/DCCPS requirements, unl ess the standard at the site is more stringent. The records for all studies 
performed under an IND will be mai ntained, at a minimum, for tw o years after the approval of a New 
Drug Application (NDA). For NCI/DCCPS, records will be retained  for at least three years after the 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 34 of 43 
 completion of the research. NCI will be notified prior to the p lanned destruction of any materials. The 
records should be accessible for inspection and copying by auth orized persons of the Food and Drug 
Administration. If the study is done outside of the United Stat es, applicable regulatory requirements for 
the specific country participating in the study also apply.    13. STATISTICAL CONSIDERATIONS 
 
13.1 Study Design/Description 
 
13.1.1. Primary Objectives  
 
To determine feasibility (recruitment, accrual, retention, adhe rence) of a RCT of a stepped-care 
telehealth mental health intervention (tailored to symptom leve l) versus enhanced usual care in 90 
post-treatment cancer survivors with moderate or severe levels of emotional distress (anxiety 
and/or depressive symptoms). 
 
13.1.2. Secondary Objectives  
 
To obtain preliminary data on the efficacy and variability of a  stepped-care telehealth mental 
health intervention (tailored to  symptom level) versus enhanced  usual care for reducing emotional 
distress (anxiety and/or depressive symptoms) in 90 post-treatm ent cancer survivors. 
 
To obtain preliminary data on the efficacy and variability of a  stepped-care telehealth mental 
health intervention (tailored to  symptom level) versus enhanced  usual care for secondary 
outcomes (sleep disturbance, fa tigue, fear of recurrence, cance r-related distress, and QOL) in 90 
post-treatment cancer survivors. 
 
To determine costs associated w ith both stepped-care telehealth  and enhanced usual care 
interventions from the perspec tive of a healthcare provider. We  will determine costs of 
intervention implementation and health care utilization in all arms over the course of the 
interventions. 
 13.1.3. Exploratory Objectives  
 
To examine potential differential effects of the intervention o n anxiety, depression, sleep 
disturbance, fatigue, fear of recurrence, and QOL, by gender, a ge, race/ethnicity, stratification 
arm (moderate, severe), and psychotropic medication use at base line. 
 
To examine mediating effects of expectancy ratings of the inter vention on anxiety and 
depression. 
 
13.2 Randomization/Stratification  
 
Participants will be stratifie d by baseline score ≥15 on the GA D-7 and/or on the PHQ-9, indicating severe 
anxiety or depressive symptoms , and by whether they qualified f or the study by the GAD-7, PHQ-9, or 
both. Participants with moderate symptoms only (8-14 on the PHQ -9 and <15 on the GAD-7 or 10-14 on 
the GAD-7 and <15 on the PHQ-9) w ill be randomized to either th e low-intensity stepped-care telehealth 
or to the enhanced usual care (EUC control) with equal probabil ity. Participants with severe symptoms 
will be randomized to either the  high-intensity stepped-care te lehealth intervention or the EUC control 
with equal probability. Participants randomized to the low-inte nsity stepped care telehealth arm who 
experience increased symptoms at  week seven and now experience severe level of symptomatology will 
receive the high-intensity inte rvention (see Section 7.1). Anal ysis will proceed as intent-to-treat using 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 35 of 43 
 their initial stepped-care telehealth assignment; we do not ant icipate that many people will change from 
moderate to severe during the study. We anticipate enrolling 45  patients in the stepped-care telehealth 
intervention and 45 in the enhanced usual care group. We will e nroll 50 participants in the moderate 
symptom strata, and 40 participants in the severe symptom strat a. Block sizes will be chosen randomly to 
ensure that future assignments cannot be inferred from previous  ones. 
 
13.3 Sample Size 
 
The sample size (N=90) is based on goals of estimating retentio n, recruitment, adherence and accrual 
rates and effect sizes to inform design of a larger efficacy tr ial. If the drop-out rate is >30%, a larger study 
may not be feasible. With N=90, we are confident that this rate  will be 30% when the observed drop-out 
rate is as large as 22% (upper limit of the one-sided 95% CI is  29.2%). Similarly, the lower limit of a one-
sided 95% confidence interval for the recruitment rate can be e stimated within 8.2% of the observed rate 
if we approach at least 100 par ticipants to recruit 90, and the  lower limit of a one-sided 95% confidence 
interval for the adherence can be  estimated within 8.7% of the observed rate with N=90. Using the normal 
approximation to the Poisson, we can estimate the lower limit o f the one-sided 95% confidence interval of 
the accrual rate within approximate ly 2 people per month if the  observed rate is 11 people per month. To 
compare differences between the groups on changes in the PHQ-9 and GAD-7 scores, we can estimate the 
intervention effect within 0.46 SD with a sample size of 36/ group (stepped-care telehealth , enhanced 
usual care), allowing 20% dropout of the 45/group randomized. T his corresponds to 2.7 points on PHQ-9 
and 1.9 points on GAD-7 using SDs from studies of change in the  measures of 5.8 and 4.2 points, 
respectively.51,73–75   
 
13.4 Primary Objective, Endpoint(s), Analysis Plan 
 
For Objective 1.1.1, recruitmen t, accrual, retention, and adher ence rates will be calculated. To determine 
the recruitment rate, we will track number of eligible particip ants and percent who agree to participate. 
Accrual rates will be calculated by calculating the mean number  of participants recruited per month. 
Study retention will be estimated by the proportion of particip ants who complete the Week 7 and 13 
visits. Intervention adherence w ill be estimated as the mean pe rcentage of therapy or check-in sessions 
each participant completes. Drop-out is defined as 100% minus t he dropout %. 95% confidence intervals 
will be calculated for each measu re to quantify uncertainty in the estimates and to determine if the lower 
(recruitment, accrual) or upper (retention, adherence) limit wo uld indicate lack of feasibility for future 
work.   
13.5 Secondary Objectives, Endpoints, Analysis Plans 
 
For Objective 1.2.1, baseline d escriptive statistics will be co mpared by intervention arm using chi-square 
tests for categorical variables and ANOVA for continuous variab les. Due to randomization, we do not 
anticipate differences by intervention arm; if they are found, we will adjust for them in the analyses for 
Objectives 1.2.1, 1.2.2, 1.2.3, a nd 1.2.4. The W orking Alliance  Inventory will be summarized using 
descriptive statistics.    
Depression and anxiety outcom es (PHQ-9 and GAD-7) will be analy zed using mixed-model analysis of 
covariance (ANCOVA) to account for intra-individual correlation s among longitudinal measures. The 
model will contain terms for the intervention group, baseline v alue of the outcome, therapist or site staff 
person completing check-in calls, psychotropic medications use,  a time effect (mid-, post-intervention), 
and the time by intervention interaction term (to test whether the intervention effects vary by time). 
Because participants may exhibit moderate or severe levels of e ither depression or anxiety, we will create 
a combined variable that indicates if a participant had moderat e/severe depression or anxiety at mid- or 
post-intervention. Each stepped- care telehealth group will be c ompared with EUC using a GEE approach 
with a logit link to determine if rates of the combined outcome  differ at mid- or post-intervention. Other 
outcome measures (sleep disturb ance, fatigue, fear of recurrenc e, cancer-related distress, and quality of 
life) will be analyzed using ANC OVA at week 13 to meet objectiv e 1.2.2.  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 36 of 43 
  
For Objective 1.2.3, we will cal culate total cost of the steppe d-care telehealth (low intensity, high 
intensity) and the EUC interven tions and average cost/survivor screened and randomized to each trial 
arm. Total cost includes costs of intervention implementation a nd health care costs for each participant.  
 Implementation costs will be det ermined using data on time spen t on intervention activities reported in 
the tracking logs. Time spent on the intervention includes i) t raining personnel to screen and deliver the 
intervention including time of trainer and trainees; ii) time s pent by interventionists on intervention 
activities, including screening, scheduling and delivering the phone sessions, and documenting 
contacts/progress; iii) phone charges; and iv) other supply cos ts (e.g., CBT workbooks). Cost of time will 
be valued using wage rates based  on national averages for resea rch staff and psychothe rapists. Other costs 
(e.g., telephone charges and prin ted materials) will be valued using project records on expenses incurred. 
We will sum all costs related to each intervention to obtain th e total cost of implementing each. Total 
costs in each study arm will be d ividing by the number of patie nts served to obtain the average cost per 
patient. Sensitivity analyses w ill be conducted to assess how i mplementation costs vary depending on the 
inputs used, such as the salaries of interventionists or superv isors.  
 Health care cost will be determined using data from self-report ed utilization of heath care services 
(Cornell Services Index).
66 To calculate the costs related  to these health care events, we  will use published 
data on average costs of these events or data from sources such  as the Medicare Fee Schedule and/or the 
Medical Expenditure Panel Surve y. We will conduct analyses to e xamine the impact of the stepped-care 
interventions on health care utilization and costs: similar to analyses specified above for Objective 1.2.1, 
we will use linear models with u tilization or costs as the depe ndent variable, and the arm assignment as 
the independent variable. Because the distribution of costs is usually skewed, we will consider using a 
generalized linear model with a gamma link. 
 
13.6 Exploratory Objectives, Endpoints, Analysis Plans 
 
We will perform stratified subgro up analysis of the outcomes in  Objectives 1.2.1 and 1.2.2. by gender, 
age, race/ethnicity, stratification arm (moderate, severe), and  psychotropic medication use at baseline to 
meet Objective 1.3.1 using ANCOV A at week 13.  To analyze Objec tive 1.3.2, we will use a mediation 
approach to examine whether expectancy ratings mediate the rela tionship between the intervention and 
the outcomes of interest (PHQ-9 , GAD-7, or the co mbined outcome ) at the intervention mid-point or end.  
First, we will examine whether th e expectancy rating score is  a significant predictor of the outcome in the 
mixed-model analysis of covariance (ANCOVA) model with terms fo r the expectancy rating score, 
baseline value of the outcome, t herapist or site staff person c onducting check-in calls, psychotropic 
medications use, a time effect ( mid-, post-intervention), and t he time by intervention expectancy score 
term (to test whether the expectancy score effects vary by time ).  Then we will fit the same model with 
the intervention effect, expectan cy rating score, and their int eractions with each other and time. If the 
effect for the mediator is significant in this model and the pa rameter estimate of the intervention effect is 
smaller than in the analysis of Objective 1.2.1 it will indicat e evidence of mediation. 
 
13.7 Reporting and Exclusions 
 
Unless we receive written or verbal withdrawal of consent, we w ill try to reach every participant for 
telephone calls, telephone sessi ons, and assessments as outline d in the protocol. 
 The dataset used in the analysis o f Objective 1.1.1 will includ e all eligible participants to calculate 
recruitment rates. Accrual, rete ntion, and adherence will be ca lculated on the participants who consent to 
participate in the study.  The a nalysis of the secondary object ives and exploratory objective will include 
all participants who consent to  participate in the study. The A NOVA models used for the secondary 
objectives use data from all available time points and allows f or data to be missing at random. For the 
analyses of the secondary objectives and the exploratory object ive, we will use an intent-to-treat 
approach. If participants are m oved from low intensity to high intensity they will be analyzed using the 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 37 of 43 
 low intensity assignment (intent  to treat). In exploratory mode ls, we will analyze the impact of adherence 
by including it as a predictor.  
 13.8 Evaluation of Response 
 
All participants in the study who complete the PHQ-9 and GAD-7 at Week 13 will be evaluable for 
response to the intervention.  I n sensitivity analyses, we will  evaluate how imputation of these values 
utilizing either baseline or Week 7 data impact study conclusio ns. Note that this is a feasibility study and 
analyses of the intervention effects will be used to plan futur e studies, not to demonstrate efficacy. 
 
  
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 38 of 43 
 REFERENCES 
 
1.  Armes J, Crowe M, Colbourne  L, Morgan H, Murrells T, Oakley  C, Palmer N, Ream E, 
Young A, Richardson A. Patients’  supportive care needs beyond t he end of cancer treatment: 
a prospective, longitudinal survey. JClinOncol . 2009;27(1527-7755 (Electronic)):6172-6179. 
2.  Alfano CM, Rowland JH. Recovery issues in cancer survivorsh ip: a new challenge for 
supportive care. Cancer J . 2006;12(1528-9117 (Print)):432-443. 
3.  Hodgkinson K, Butow P, Fuchs A, Hunt GE, Stenlake A, Hobbs KM, Brand A, Wain G. 
Long-term survival from gynecologic cancer: psychosocial outcom es, supportive care needs 
and positive outcomes. GynecolOncol . 2007;104(0090-8258 (Print)):381-389. 
4.  Jacobsen PB, Donovan KA, Swaine ZN. Management of anxiety a nd depression in adult 
cancer patients: Toward an eviden ce-based approach. In: Chang A E, Ganz PA, Hayes DF, 
eds. Oncology: An Evidence-Based Approach . Philadelphia, PA: Springer; 2006:1552-1579. 
5.  Jefford M, Karahalios E, Po llard A, Baravelli C, Carey M, F ranklin J, Aranda S, Schofield P. 
Survivorship issues following tr eatment completion--results fro m focus groups with 
Australian cancer survivors and health professionals. JCancer Surviv . 2008;2(1932-2267 
(Electronic)):20-32. doi:10.1007/s11764-008-0043-4. 
6.  Stanton AL, Bower JE, Low CA. Posttraumatic Growth After Ca ncer; Handbook of 
Posttraumatic Growth: Research and Practice. In: G.Calhoun, R.G .Tedeschi, eds. Handbook 
of Posttraumatic Growth: Research and Practice . Mahway, NJ: Lawrence Erlbaum 
Associates; 2006:138-175. 
7.  Andersen BL, Yang HC, Farrar WB, Golden-Kreutz DM, Emery CF , Thornton LM, Young 
DC, Carson WE III. Psychologic intervention improves survival f or breast cancer patients: a 
randomized clinical trial. Cancer . 2008;113(0008-543X (Print)):3450-3458. 
doi:10.1002/cncr.23969. 
8.  Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De VJ. Predictors of 
depressive symptoms 12 months after surgical treatment of early -stage breast cancer. 
Psychooncology . 2009;18(1099-1611 (Electronic)):1230-1237. doi:10.1002/pon.15 18. 
9.  Ganz PA, Kwan L, Stanton A L, Krupnick JL, Rowland JH, Meyer owitz BE, Bower JE, 
Belin TR. Quality of life at the end of primary treatment of br east cancer: first results from 
the moving beyond cancer randomized trial. J NatlCancer Inst . 2004;96(1460-2105 
(Electronic)):376-387. 
10.  Kim SH, Son BH, Hwang SY, Han W, Yang JH, Lee S, Yun YH. F atigue and depression in 
disease-free breast cancer survivors: prevalence, correlates, a nd association with quality of 
life. J PainSymptomManage . 2008;35(0885-3924 (Print)):644-655. 
doi:10.1016/j.jpainsymman.2007.08.012. 
11.  Philip EJ, Merluzzi TV, Zhang Z, Heitzmann CA. Depression and cancer survivorship: 
importance of coping self-efficacy in post-treatment survivors.  Psychooncology . 
2013;22(1099-1611 (Electronic)):987-994. doi:10.1002/pon.3088. 
12.  Punnen S, Cowan JE, Dunn LB , Shumay DM, Carroll PR, Cooper berg MR. A longitudinal 
study of anxiety, depression and distress as predictors of sexu al and urinary quality of life in 
men with prostate cancer. BJUInt . 2013;112(1464-410X (Electronic)):E67-E75. 
doi:10.1111/bju.12209. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 39 of 43 
 13.  Scheffold K, Mehnert A, Mulle r V, Koch U, Harter M, Vehlin g S. Sources of meaning in 
cancer patients - influences on gl obal meaning, anxiety and dep ression in a longitudinal 
study. EurJ Cancer Care Engl . 2014;23(1365-2354 (Electronic)):472-480. 
doi:10.1111/ecc.12152. 
14.  Vahdaninia M, Omidvari S, Montazeri A. What do predict anx iety and depression in breast 
cancer patients? A follow-up study. Soc Psychiatry PsychiatrEpidemiol . 2010;45(1433-9285 
(Electronic)):355-361. 
15.  Jacobsen PB, Jim HS. Psychos ocial interventions for anxiet y and depression in adult cancer 
patients: achievements and challenges. CA Cancer JClin . 2008;58(0007-9235 (Print)):214-
230. 
16.  Ristvedt SL, Trinkaus KM. Trait anxiety as an independent predictor of poor health-related 
quality of life and post-traumatic  stress symptoms in rectal ca ncer. BrJHealth Psychol . 
2009;14(1359-107X (Print)):701-715. 
17.  Brown LF, Kroenke K, Theobald DE, Wu J, Tu W. The associat ion of depression and 
anxiety with health-related quality of life in cancer patients with depression and/or pain. 
Psychooncology . 2010;19(1099-1611 (Electronic)):734-741. doi:10.1002/pon.1627 . 
18.  Deimling GT, Bowman KF, Stern s S, Wagner LJ, Kahana B. Can cer-related health worries 
and psychological distress among ol der adult, long-term cancer survivors. Psychooncology . 
2006. 
19.  Diefenbach M, Mohamed NE, Horwitz E, Pollack A. Longitudin al associations among 
quality of life and its predictors in patients treated for pros tate cancer: the moderating role of 
age. PsycholHealth Med . 2008;13(1354-8506 (Print)):146-161. 
doi:10.1080/13548500701352008. 
20.  Sharma N, Hansen CH, O’Connor M, Thekkumpurath P, Walker J , Kleiboer A, Murray G, 
Espie C, Storey D, Sharpe M, Fleming L. Sleep problems in cance r patients: prevalence and 
association with distress and pain. Psychooncology . 2012;21(1099-1611 (Electronic)):1003-
1009. doi:10.1002/pon.2004. 
21.  Trudel-Fitzgerald C, Savard J, Ivers H. Which symptoms com e first? Exploration of 
temporal relationships between cancer-related symptoms over an 18-month period. Ann 
Behav Med . 2013;45(1532-4796 (Electronic)):329-337. doi:10.1007/s12160-0 12-9459-1. 
22.  Satin JR, Linden W, Phillips MJ. Depression as a predictor  of disease progression and 
mortality in cancer patients: a meta-analysis. Cancer . 2009;115(0008-543X (Print)):5349-
5361. doi:10.1002/cncr.24561. 
23.  Pinquart M, Duberstein PR. Depression and cancer mortality : a meta-analysis. PsycholMed . 
2010;40(1469-8978 (Electronic)):1797-1810. doi:10.1017/S0033291 709992285. 
24.  Hewitt ME. National Cancer Policy Board (U.S.), & Committe e on cancer survivorship: 
Improving care and quality of life. Inst Med . 2007. 
25.  Rowland JH, Hewitt M, Ganz PA . Cancer survivorship: a new challenge in delivering 
quality cancer care. JClinOncol . 2006;24(1527-7755 (Electronic)):5101-5104. 
26.  Carlson LE, Bultz BD. Benef its of psychosocial oncology ca re: improved quality of life and 
medical cost offset. Health QualLifeOutcomes . 2003;1(1477-7525 (Electronic)):8. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 40 of 43 
 27.  Weaver KE, Geiger AM, Lu L, Case LD. Rural-urban dispariti es in health status among US 
cancer survivors 3055. Cancer . 2013;119(1097-0142 (Electronic)):1050-1057. 
doi:10.1002/cncr.27840. 
28.  Burris JL, Andrykowski M. Disparities in mental health bet ween rural and nonrural cancer 
survivors: a preliminary study. Psychooncology . 2010;19(1099-1611 (Electronic)):637-645. 
doi:10.1002/pon.1600. 
29.  Andrykowski MA, Burris JL. Use of formal and informal ment al health resources by cancer 
survivors: differences between rural and nonrural survivors and  a preliminary test of the 
theory of planned behavior. Psychooncology . 2009. 
30.  Stamm BH, Piland NF, Lambert D, Speck NC. A Rural Perspect ive on Health Care for the 
Whole Person. Prof Psychol Res Pract . 2007;38(3):298-304. 
31.  American Psychological Association (2001). Caring for the Rural Community: 2000-2001 
Report .; 2001. 
32.  Brenes GA, Danhauer SC, Lyl es MF, Hogan PE, Miller ME. Tel ephone-Delivered Cognitive 
Behavioral Therapy and Telephone -Delivered Nondirective Support ive Therapy for Rural 
Older Adults With Generalized A nxiety Disorder: A Randomized Cl inical Trial. JAMA 
Psychiatry . 2015;72(10):1012-1020. doi:10.1001/jamapsychiatry.2015.1154. 
33.  United States Department of Agriculture. USDA Economic Research Service - Rural Urban 
Continuum Codes Documentation .; 2014. _http://www.ers.usda .gov/data-products/rural-
urban-continuum-codes/documentation.aspx#.UurEFrQglhk_. Accesse d January 30, 2014. 
34.  Welsh KA, Breitner JCS, Magr uder-Habib KM. Detection of de mentia in the elderly using 
telephone screening of cognitive status. Neuropsychiatry Neuropsychol Behav Neurol . 
1993;(6):103-110. 
35.  Stanley MA, Beck JG, Glassco JD. Treatment of generalized anxiety in older adults: A 
preliminary comparison of cogn ititive-behavior and supportive a pproaches. Behav Ther . 
1996;27:565-581. 
36.  Stanley MA, Hopko DR, Dief enbach GJ, Bourland SL, Rodrigue z H, Wagener P. Cognitive-
behavior therapy for late-life generalized anxiety disorder in primary care: preliminary 
findings. Am J Geriatr Psychiatry . 2003;11(1064-7481 (Print)):92-96. 
37.  Kroenke K, Theobald D, Nort on K, Sanders R, Schlundt S, Mc Calley S, Harvey P, 
Iseminger K, Morrison G, Carpenter JS, Stubbs D, Jacks R, Carne y-Doebbeling C, Wu J, Tu 
W. The Indiana Cancer Pain and Depression (INCPAD) trial Design  of a telecare 
management intervention for cancer-related symptoms and baselin e characteristics of study 
participants. Gen Hosp Psychiatry . 2009;31(1873-7714 (Electronic)):240-253. 
doi:10.1016/j.genhosppsych.2009.01.007. 
38.  Badger T, Segrin C, Pasvogel A, Lopez AM. The effect of ps ychosocial interventions 
delivered by telephone and videophone on quality of life in ear ly-stage breast cancer 
survivors and their supportive partners. J TelemedTelecare . 2013;19(1758-1109 
(Electronic)):260-265. doi:10.1177/1357633X13492289. 
39.  Meneses K, McNees P, Azuero A, Loerzel VW, Su X, Hassey LA . Preliminary evaluation of 
psychoeducational support interv entions on quality of life in r ural breast cancer survivors 
after primary treatment. Cancer Nurs . 2009;32(1538-9804 (Electronic)):385-397. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 41 of 43 
 doi:10.1097/NCC.0b013e3181a850e6. 
40.  Freeman LW, White R, Ratcliff CG, Sutton S, Stewart M, Pal mer JL, Link J, Cohen L. A 
randomized trial comparing live and telemedicine deliveries of an imagery-based behavioral 
intervention for breast cancer su rvivors: reducing symptoms and  barriers to care. 
Psychooncology . 2014;(1099-1611 (Electronic)). doi:10.1002/pon.3656. 
41.  Head BA, Studts JL, Bumpous  JM, Gregg JL, Wilson L, Keeney  C, Scharfenberger JA, 
Pfeifer MP. Development of a telehealth intervention for head a nd neck cancer patients. 
TelemedJ EHealth . 2009;15(1556-3669 (Electronic)):44-52. doi:10.1089/tmj.2008.0 061. 
42.  Zernicke KA, Campbell TS, Speca M, McCabe-Ruff K, Flowers S, Carlson LE. A 
randomized wait-list controlled trial of feasibility and effica cy of an online mindfulness-
based cancer recovery program: the eTherapy for cancer applying  mindfulness trial. 
Psychosom Med . 2014;76(1534-7796 (Electronic)):257-267. 
doi:10.1097/PSY.0000000000000053. 
43.  U.S. Census Bureau, 2000. US Population Living in Urban vs. Rural Areas .; 2000. 
44.  Barlow DH, Rapee RM, Brown T A. Behavioral treatment of gen eralized anziety disorder. 
Behav Ther . 1992;23(4):551-571. 
45.  Clark DM, Salkovskis PM, Hack mann A, Wells A, Ludgate J, G elder M. Brief cognitive 
therapy for panic disorder: a randomized controlled trial. JConsult ClinPsychol . 
1999;67(0022-006X (Print)):583-589. 
46.  Larsen DL, Attkisson CC, Har greaves WA, Nguyen TD. Assessm ent of client/patient 
satisfaction: development of a general scale. Eval ProgramPlann . 1979;2(0149-7189 
(Print)):197-207. 
47.  Akkerman R, Stanley M, Aver ill P, Novy D, Snyder A, Diefen bach G. Recruiting Older 
Adults With Generalized Anxiety Disorder. J Ment Health Aging . 2001;7:385-394. 
48.  Tracey TJ, Kokotovic AM. Factor structure of the Working A lliance Inventory. Psychol 
Assess . 1989;(1):207-210. 
49.  Hewitt ME, National Cancer Policy Board (U.S.), Committee on Cancer Survivorship: 
Improving Care and Quality of Life. From Cancer Patient to Cancer Survivor  : Lost in 
Transition . Washington, D.C.: National Academies Press,; 2006. 
50.  Busseri MA, Tyler JD. Inter changeability of the Working Al liance Inventory and Working 
Alliance Inventory, Short Form. PsycholAssess . 2003;15(1040-3590 (Print)):193-197. 
51.  Titov N, Dear BF, McMillan D, Anderson T, Zou J, Sunderlan d M. Psychometric 
comparison of the PHQ-9 and BDI-II for measuring response durin g treatment of depression. 
Cogn Behav Ther . 2011;40(1651-2316 (Electronic)):126-136. 
doi:10.1080/16506073.2010.550059. 
52.  Luckett T, Butow PN, King MT, Oguchi M, Heading G, Hackl N A, Rankin N, Price MA. A 
review and recommendations for op timal outcome measures of anxi ety, depression and 
general distress in studies eval uating psychosocial interventio ns for English-speaking adults 
with heterogeneous cancer diagnoses. Support Care Cancer . 2010;18(1433-7339 
(Electronic)):1241-1262. 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 42 of 43 
 53.  Spitzer RL, Kroenke K, Williams  JB, Lowe B. A brief measur e for assessing generalized 
anxiety disorder: the GAD-7. ArchInternMed . 2006;166(0003-9926 (Print)):1092-1097. 
54.  Seo EH, Lee DY, Kim SG, Kim K W, Kim  do H, K im BJ, Kim MD,  Kim SY, Kim YH, Kim 
JL, Kim JW, Moon SW, Park JH, R yu SH, Yoon JC, Lee NJ, Lee CU, Jhoo JH, Choo LH, 
Woo JI. Validity of the telephone interview for cognitive statu s (TICS) and modified TICS 
(TICSm) for mild cognitive imparm ent (MCI) and dementia screeni ng. Arch Gerontol 
Geriatr . 2011;52(1872-6976 (Electronic)): e26-e30. doi:10.1016/j.archge r.2010.04.008. 
55.  Simard S, Savard J. Fear of Cancer Recurrence Inventory: d evelopment and initial validation 
of a multidimensional measure of fear of cancer recurrence. Support Care Cancer Off J 
Multinatl Assoc Support Care Cancer . 2009;17(3):241-251. doi:10.1007/s00520-008-0444-y 
56.  Bastien CH, Vallieres A, Mor in CM. Validation of the Insom nia Severity Index as an 
outcome measure for insomnia research. Sleep Med . 2001;2(1878-5506 (Electronic)):297-
307. 
57.  Morin CM, Belleville G, Bela nger L, Ivers H. The Insomnia Severity Index: psychometric 
indicators to detect insomnia cases and evaluate treatment resp onse. Sleep . 2011;34(1550-
9109 (Electronic)):601-608. 
58.  Cella D, Gershon R. PROMIS Assessment Center User Manual Version 6.0 .; 2010. 
_www.nihpromis.org_. 
59.  Ware JE Jr, Sherbourne CD. T he MOS 36-item short-form heal th survey (SF-36). I. 
Conceptual framework and item selection. MedCare . 1992;30(0025-7079 (Print)):473-483. 
60.  McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short- Form Health Survey (SF-
36): II. Psychometric and clini cal tests of validity in measuri ng physical and mental health 
constructs. MedCare . 1993;31(0025-7079 (Print)):247-263. 
61.  McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36- item Short-Form Health 
Survey (SF-36): III. Tests of data quality, scaling assumptions , and reliability across diverse 
patient groups. MedCare . 1994;32(0025-7079 (Print)):40-66. 
62.  Weiss D. The Impact of Events Scale-Revised. In: Assessing Psychological Trauma and 
PTSD: A Practitioner’s Handbook . 2nd ed. New York: Guilford Press; 2007:168-189. 
63.  Salsman JM, Schalet BD, Andrykowski MA, Cella D. The impac t of events scale: a 
comparison of frequency versus severity approaches to measuring  cancer-specific distress. 
Psychooncology . 2015;24(12):1738-1745. doi:10.1002/pon.3784. 
64.  Borkovec TD, Nau SD. Credib ility of analogue therapy ratio nales. Behav Ther Exp 
Psychiatry . 1972;3(257):260. 
65.  Horvath AO, Greenberg LS. D evelopment and validation of th e Working Alliance Inventory. 
J Couns Psychol . 1989;36:223-233. 
66.  Sirey JA, Meyers BS, Teresi JA, Bruce ML, Ramirez M, Raue PJ, Perlick DA, Holmes D. 
The Cornell Service Index as a measure of health service use. Psychiatr Serv . 2005;56(1075-
2730 (Print)):1564-1569. doi:10.1176/appi.ps.56.12.1564. 
67.  Weaver KE, Aziz NM, Arora NK, Forsythe LP, Hamilton AS, Oa kley-Girvan I, Keel G, 
Bellizzi KM, Rowland JH. Follow-up care experiences and perceiv ed quality of care among 
   WF-30917CD 
  Amendment 5, Protocol Version Date 12/09/2020 
 
Page 43 of 43 
 long-term survivors of breast, prostate, colorectal, and gyneco logic cancers. J OncolPract . 
2014;10(1935-469X (Electronic)):e231-e239. doi:10.1200/JOP.2013 .001175. 
68.  Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of  a brief depression severity 
measure. J Gen Intern Med . 2001;16(0884-8734 (Print)):606-613. 
69.  Hinz A, Mehnert A, Kocaleven t R-D, Brähler E, Forkmann T, Singer S, Schulte T. 
Assessment of depression severity  with the PHQ-9 in cancer pati ents and in the general 
population. BMC Psychiatry . 2016;16:22. doi:10.1186/s12888-016-0728-6. 
70.  Lowe B, Decker O, Muller S, Brahler E, Schellberg D, Herzo g W, Herzberg PY. Validation 
and standardization of the Generalized Anxiety Disorder Screene r (GAD-7) in the general 
population. MedCare . 2008;46(0025-7079 (Print)):266-274. 
71.  Gagnon C, Bélanger L, Ivers H , Morin CM. Validation of the  Insomnia Severity Index in 
primary care. J Am Board Fam Med JABFM . 2013;26(6):701-710. 
doi:10.3122/jabfm.2013.06.130064. 
72.  Garcia SF, Cella D, Clauser  SB, Flynn KE, Lad T, Lai J-S, Reeve BB, Smith AW, Stone 
AA, Weinfurt K. Standardizing pa tient-reported outcomes assessm ent in cancer clinical 
trials: a patient-reported outcom es measurement information sys tem initiative. J Clin Oncol 
Off J Am Soc Clin Oncol . 2007;25(32):5106-5112. doi:10.1200/JCO.2007.12.2341. 
73.  Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Mon itoring depression treatment 
outcomes with the patient health questionnaire-9. Med Care . 2004;42(0025-7079 
(Print)):1194-1201. 
74.  Pilkonis PA, Yu L, Dodds NE, Johnston KL, Maihoefer CC, La wrence SM. Validation of 
the depression item bank from the Patient-Reported Outcomes Mea surement Information 
System (PROMIS) in a three-month observational study. J PsychiatrRes . 2014;56(1879-
1379 (Electronic)):112-119. doi:10.1016/j.jpsychires.2014.05.01 0. 
75.  Dear BF, Titov N, Sunderla nd M, McMillan D, Anderson T, Lo rian C, Robinson E. 
Psychometric comparison of the generalized anxiety disorder sca le-7 and the Penn State 
Worry Questionnaire for measuring response during treatment of generalised anxiety 
disorder. Cogn Behav Ther . 2011;40(1651-2316 (Electronic)):216-227. 
doi:10.1080/16506073.2011.582138. 
76. Thekkumpurath P, Walker J, Butcher I, et al: Screening for major depression in cancer 
outpatients:  The diagnostic accura cy of the 9-item patient hea lth questionnaire.  Cancer 
117:218-227, 2011 
77. Manea L, Gilbody S, McMillan D:  Optimal cut-off score for diagnosing depression with the 
Patient Health Questionnaire (PHQ-(): A meta-analysis. CMAJ 184 :E191-E196, 2012 
 
 